Does contemporary vancomycin dosing achieve therapeutic targets in a heterogeneous clinical cohort of critically ill patients? Data from the multinational DALI study
Identifieur interne : 001637 ( Pmc/Corpus ); précédent : 001636; suivant : 001638Does contemporary vancomycin dosing achieve therapeutic targets in a heterogeneous clinical cohort of critically ill patients? Data from the multinational DALI study
Auteurs : Stijn Blot ; Despoina Koulenti ; Murat Akova ; Matteo Bassetti ; Jan J. De Waele ; George Dimopoulos ; Kirsi-Maija Kaukonen ; Claude Martin ; Philippe Montravers ; Jordi Rello ; Andrew Rhodes ; Therese Starr ; Steven C. Wallis ; Jeffrey Lipman ; Jason A. RobertsSource :
- Critical Care [ 1364-8535 ] ; 2014.
Abstract
The objective of this study was to describe the pharmacokinetics of vancomycin in ICU patients and to examine whether contemporary antibiotic dosing results in concentrations that have been associated with favourable response.
The Defining Antibiotic Levels in Intensive Care (DALI) study was a prospective, multicentre pharmacokinetic point-prevalence study. Antibiotic dosing was as per the treating clinician either by intermittent bolus or continuous infusion. Target trough concentration was defined as ≥15 mg/L and target pharmacodynamic index was defined as an area under the concentration-time curve over a 24-hour period divided by the minimum inhibitory concentration of the suspected bacteria (AUC0–24/MIC ratio) >400 (assuming MIC ≤1 mg/L).
Data of 42 patients from 26 ICUs were eligible for analysis. A total of 24 patients received vancomycin by continuous infusion (57%). Daily dosage of vancomycin was 27 mg/kg (interquartile range (IQR) 18 to 32), and not different between patients receiving intermittent or continuous infusion. Trough concentrations were highly variable (median 27, IQR 8 to 23 mg/L). Target trough concentrations were achieved in 57% of patients, but more frequently in patients receiving continuous infusion (71% versus 39%;
This study demonstrated large interindividual variability in vancomycin pharmacokinetic and pharmacodynamic target attainment in ICU patients. These data suggests that a re-evaluation of current vancomycin dosing recommendations in critically ill patients is needed to more rapidly and consistently achieve sufficient vancomycin exposure.
Url:
DOI: 10.1186/cc13874
PubMed: 24887569
PubMed Central: 4075416
Links to Exploration step
PMC:4075416Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Does contemporary vancomycin dosing achieve therapeutic targets in a heterogeneous clinical cohort of critically ill patients? Data from the multinational DALI study</title><author><name sortKey="Blot, Stijn" sort="Blot, Stijn" uniqKey="Blot S" first="Stijn" last="Blot">Stijn Blot</name><affiliation><nlm:aff id="I1">Department of Internal Medicine, Faculty of Medicine & Health Science, Ghent University, Sint-Pietersnieuwstraat 25, 9000 Ghent, Belgium</nlm:aff></affiliation></author><author><name sortKey="Koulenti, Despoina" sort="Koulenti, Despoina" uniqKey="Koulenti D" first="Despoina" last="Koulenti">Despoina Koulenti</name><affiliation><nlm:aff id="I2">Burns Trauma and Critical Care Research Centre, The University of Queensland, Butterfield Street, Herston, Brisbane, QLD 4029, Australia</nlm:aff></affiliation><affiliation><nlm:aff id="I3">Royal Brisbane and Women’s Hospital, Butterfield Street, Herston, Brisbane, QLD 4006, Australia</nlm:aff></affiliation><affiliation><nlm:aff id="I4">Attikon University Hospital, 1, Rimini Street, Haidari, 124 62 Athens, Greece</nlm:aff></affiliation></author><author><name sortKey="Akova, Murat" sort="Akova, Murat" uniqKey="Akova M" first="Murat" last="Akova">Murat Akova</name><affiliation><nlm:aff id="I5">Hacettepe University, School of Medicine, 06100 Sıhhiye, Ankara, Turkey</nlm:aff></affiliation></author><author><name sortKey="Bassetti, Matteo" sort="Bassetti, Matteo" uniqKey="Bassetti M" first="Matteo" last="Bassetti">Matteo Bassetti</name><affiliation><nlm:aff id="I6">Azienda Ospedaliera Universitaria Santa Maria della Misericordia, Piazzale Santa Maria della Misericordia, 15, 33100 Udine, Italy</nlm:aff></affiliation></author><author><name sortKey="De Waele, Jan J" sort="De Waele, Jan J" uniqKey="De Waele J" first="Jan J" last="De Waele">Jan J. De Waele</name><affiliation><nlm:aff id="I7">Ghent University Hospital, De Pintelaan 185, 9000 Ghent, Belgium</nlm:aff></affiliation></author><author><name sortKey="Dimopoulos, George" sort="Dimopoulos, George" uniqKey="Dimopoulos G" first="George" last="Dimopoulos">George Dimopoulos</name><affiliation><nlm:aff id="I4">Attikon University Hospital, 1, Rimini Street, Haidari, 124 62 Athens, Greece</nlm:aff></affiliation></author><author><name sortKey="Kaukonen, Kirsi Maija" sort="Kaukonen, Kirsi Maija" uniqKey="Kaukonen K" first="Kirsi-Maija" last="Kaukonen">Kirsi-Maija Kaukonen</name><affiliation><nlm:aff id="I8">Helsinki University Central Hospital, Haartmaninkatu 3, 00029 Helsinki, Uusimaa, Finland</nlm:aff></affiliation><affiliation><nlm:aff id="I9">Australian and New Zealand Intensive Care Research Centre (ANZIC RC), Department of Epidemiology and Preventive Medicine, Monash University, 99 Commercial Road, Melbourne, VIC 3004, Australia</nlm:aff></affiliation></author><author><name sortKey="Martin, Claude" sort="Martin, Claude" uniqKey="Martin C" first="Claude" last="Martin">Claude Martin</name><affiliation><nlm:aff id="I10">Hospital Nord, Chemin des Bourrely, 13015 Marseille, France</nlm:aff></affiliation><affiliation><nlm:aff id="I11">AzuRea Group, France</nlm:aff></affiliation></author><author><name sortKey="Montravers, Philippe" sort="Montravers, Philippe" uniqKey="Montravers P" first="Philippe" last="Montravers">Philippe Montravers</name><affiliation><nlm:aff id="I12">Centre Hospitalier Universitaire Bichat-Claude Bernard, AP-HP, Université Paris VII, 46 Rue Henri Huchard, 75018 Paris, France</nlm:aff></affiliation></author><author><name sortKey="Rello, Jordi" sort="Rello, Jordi" uniqKey="Rello J" first="Jordi" last="Rello">Jordi Rello</name><affiliation><nlm:aff id="I13">CIBERES, Vall d'Hebron Institute of Research, Universitat Autonoma de Barcelona, Passeig de la Vall d’Hebron, 119-129, 08035 Barcelona, Spain</nlm:aff></affiliation></author><author><name sortKey="Rhodes, Andrew" sort="Rhodes, Andrew" uniqKey="Rhodes A" first="Andrew" last="Rhodes">Andrew Rhodes</name><affiliation><nlm:aff id="I14">St George’s Healthcare NHS Trust and St George’s University of London, Cranmer Terrace, London SW17 0RE, UK</nlm:aff></affiliation></author><author><name sortKey="Starr, Therese" sort="Starr, Therese" uniqKey="Starr T" first="Therese" last="Starr">Therese Starr</name><affiliation><nlm:aff id="I2">Burns Trauma and Critical Care Research Centre, The University of Queensland, Butterfield Street, Herston, Brisbane, QLD 4029, Australia</nlm:aff></affiliation><affiliation><nlm:aff id="I3">Royal Brisbane and Women’s Hospital, Butterfield Street, Herston, Brisbane, QLD 4006, Australia</nlm:aff></affiliation></author><author><name sortKey="Wallis, Steven C" sort="Wallis, Steven C" uniqKey="Wallis S" first="Steven C" last="Wallis">Steven C. Wallis</name><affiliation><nlm:aff id="I2">Burns Trauma and Critical Care Research Centre, The University of Queensland, Butterfield Street, Herston, Brisbane, QLD 4029, Australia</nlm:aff></affiliation></author><author><name sortKey="Lipman, Jeffrey" sort="Lipman, Jeffrey" uniqKey="Lipman J" first="Jeffrey" last="Lipman">Jeffrey Lipman</name><affiliation><nlm:aff id="I2">Burns Trauma and Critical Care Research Centre, The University of Queensland, Butterfield Street, Herston, Brisbane, QLD 4029, Australia</nlm:aff></affiliation><affiliation><nlm:aff id="I3">Royal Brisbane and Women’s Hospital, Butterfield Street, Herston, Brisbane, QLD 4006, Australia</nlm:aff></affiliation></author><author><name sortKey="Roberts, Jason A" sort="Roberts, Jason A" uniqKey="Roberts J" first="Jason A" last="Roberts">Jason A. Roberts</name><affiliation><nlm:aff id="I2">Burns Trauma and Critical Care Research Centre, The University of Queensland, Butterfield Street, Herston, Brisbane, QLD 4029, Australia</nlm:aff></affiliation><affiliation><nlm:aff id="I3">Royal Brisbane and Women’s Hospital, Butterfield Street, Herston, Brisbane, QLD 4006, Australia</nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">24887569</idno><idno type="pmc">4075416</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4075416</idno><idno type="RBID">PMC:4075416</idno><idno type="doi">10.1186/cc13874</idno><date when="2014">2014</date><idno type="wicri:Area/Pmc/Corpus">001637</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">001637</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Does contemporary vancomycin dosing achieve therapeutic targets in a heterogeneous clinical cohort of critically ill patients? Data from the multinational DALI study</title><author><name sortKey="Blot, Stijn" sort="Blot, Stijn" uniqKey="Blot S" first="Stijn" last="Blot">Stijn Blot</name><affiliation><nlm:aff id="I1">Department of Internal Medicine, Faculty of Medicine & Health Science, Ghent University, Sint-Pietersnieuwstraat 25, 9000 Ghent, Belgium</nlm:aff></affiliation></author><author><name sortKey="Koulenti, Despoina" sort="Koulenti, Despoina" uniqKey="Koulenti D" first="Despoina" last="Koulenti">Despoina Koulenti</name><affiliation><nlm:aff id="I2">Burns Trauma and Critical Care Research Centre, The University of Queensland, Butterfield Street, Herston, Brisbane, QLD 4029, Australia</nlm:aff></affiliation><affiliation><nlm:aff id="I3">Royal Brisbane and Women’s Hospital, Butterfield Street, Herston, Brisbane, QLD 4006, Australia</nlm:aff></affiliation><affiliation><nlm:aff id="I4">Attikon University Hospital, 1, Rimini Street, Haidari, 124 62 Athens, Greece</nlm:aff></affiliation></author><author><name sortKey="Akova, Murat" sort="Akova, Murat" uniqKey="Akova M" first="Murat" last="Akova">Murat Akova</name><affiliation><nlm:aff id="I5">Hacettepe University, School of Medicine, 06100 Sıhhiye, Ankara, Turkey</nlm:aff></affiliation></author><author><name sortKey="Bassetti, Matteo" sort="Bassetti, Matteo" uniqKey="Bassetti M" first="Matteo" last="Bassetti">Matteo Bassetti</name><affiliation><nlm:aff id="I6">Azienda Ospedaliera Universitaria Santa Maria della Misericordia, Piazzale Santa Maria della Misericordia, 15, 33100 Udine, Italy</nlm:aff></affiliation></author><author><name sortKey="De Waele, Jan J" sort="De Waele, Jan J" uniqKey="De Waele J" first="Jan J" last="De Waele">Jan J. De Waele</name><affiliation><nlm:aff id="I7">Ghent University Hospital, De Pintelaan 185, 9000 Ghent, Belgium</nlm:aff></affiliation></author><author><name sortKey="Dimopoulos, George" sort="Dimopoulos, George" uniqKey="Dimopoulos G" first="George" last="Dimopoulos">George Dimopoulos</name><affiliation><nlm:aff id="I4">Attikon University Hospital, 1, Rimini Street, Haidari, 124 62 Athens, Greece</nlm:aff></affiliation></author><author><name sortKey="Kaukonen, Kirsi Maija" sort="Kaukonen, Kirsi Maija" uniqKey="Kaukonen K" first="Kirsi-Maija" last="Kaukonen">Kirsi-Maija Kaukonen</name><affiliation><nlm:aff id="I8">Helsinki University Central Hospital, Haartmaninkatu 3, 00029 Helsinki, Uusimaa, Finland</nlm:aff></affiliation><affiliation><nlm:aff id="I9">Australian and New Zealand Intensive Care Research Centre (ANZIC RC), Department of Epidemiology and Preventive Medicine, Monash University, 99 Commercial Road, Melbourne, VIC 3004, Australia</nlm:aff></affiliation></author><author><name sortKey="Martin, Claude" sort="Martin, Claude" uniqKey="Martin C" first="Claude" last="Martin">Claude Martin</name><affiliation><nlm:aff id="I10">Hospital Nord, Chemin des Bourrely, 13015 Marseille, France</nlm:aff></affiliation><affiliation><nlm:aff id="I11">AzuRea Group, France</nlm:aff></affiliation></author><author><name sortKey="Montravers, Philippe" sort="Montravers, Philippe" uniqKey="Montravers P" first="Philippe" last="Montravers">Philippe Montravers</name><affiliation><nlm:aff id="I12">Centre Hospitalier Universitaire Bichat-Claude Bernard, AP-HP, Université Paris VII, 46 Rue Henri Huchard, 75018 Paris, France</nlm:aff></affiliation></author><author><name sortKey="Rello, Jordi" sort="Rello, Jordi" uniqKey="Rello J" first="Jordi" last="Rello">Jordi Rello</name><affiliation><nlm:aff id="I13">CIBERES, Vall d'Hebron Institute of Research, Universitat Autonoma de Barcelona, Passeig de la Vall d’Hebron, 119-129, 08035 Barcelona, Spain</nlm:aff></affiliation></author><author><name sortKey="Rhodes, Andrew" sort="Rhodes, Andrew" uniqKey="Rhodes A" first="Andrew" last="Rhodes">Andrew Rhodes</name><affiliation><nlm:aff id="I14">St George’s Healthcare NHS Trust and St George’s University of London, Cranmer Terrace, London SW17 0RE, UK</nlm:aff></affiliation></author><author><name sortKey="Starr, Therese" sort="Starr, Therese" uniqKey="Starr T" first="Therese" last="Starr">Therese Starr</name><affiliation><nlm:aff id="I2">Burns Trauma and Critical Care Research Centre, The University of Queensland, Butterfield Street, Herston, Brisbane, QLD 4029, Australia</nlm:aff></affiliation><affiliation><nlm:aff id="I3">Royal Brisbane and Women’s Hospital, Butterfield Street, Herston, Brisbane, QLD 4006, Australia</nlm:aff></affiliation></author><author><name sortKey="Wallis, Steven C" sort="Wallis, Steven C" uniqKey="Wallis S" first="Steven C" last="Wallis">Steven C. Wallis</name><affiliation><nlm:aff id="I2">Burns Trauma and Critical Care Research Centre, The University of Queensland, Butterfield Street, Herston, Brisbane, QLD 4029, Australia</nlm:aff></affiliation></author><author><name sortKey="Lipman, Jeffrey" sort="Lipman, Jeffrey" uniqKey="Lipman J" first="Jeffrey" last="Lipman">Jeffrey Lipman</name><affiliation><nlm:aff id="I2">Burns Trauma and Critical Care Research Centre, The University of Queensland, Butterfield Street, Herston, Brisbane, QLD 4029, Australia</nlm:aff></affiliation><affiliation><nlm:aff id="I3">Royal Brisbane and Women’s Hospital, Butterfield Street, Herston, Brisbane, QLD 4006, Australia</nlm:aff></affiliation></author><author><name sortKey="Roberts, Jason A" sort="Roberts, Jason A" uniqKey="Roberts J" first="Jason A" last="Roberts">Jason A. Roberts</name><affiliation><nlm:aff id="I2">Burns Trauma and Critical Care Research Centre, The University of Queensland, Butterfield Street, Herston, Brisbane, QLD 4029, Australia</nlm:aff></affiliation><affiliation><nlm:aff id="I3">Royal Brisbane and Women’s Hospital, Butterfield Street, Herston, Brisbane, QLD 4006, Australia</nlm:aff></affiliation></author></analytic><series><title level="j">Critical Care</title><idno type="ISSN">1364-8535</idno><idno type="eISSN">1466-609X</idno><imprint><date when="2014">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><sec><title>Introduction</title><p>The objective of this study was to describe the pharmacokinetics of vancomycin in ICU patients and to examine whether contemporary antibiotic dosing results in concentrations that have been associated with favourable response.</p></sec><sec><title>Methods</title><p>The Defining Antibiotic Levels in Intensive Care (DALI) study was a prospective, multicentre pharmacokinetic point-prevalence study. Antibiotic dosing was as per the treating clinician either by intermittent bolus or continuous infusion. Target trough concentration was defined as ≥15 mg/L and target pharmacodynamic index was defined as an area under the concentration-time curve over a 24-hour period divided by the minimum inhibitory concentration of the suspected bacteria (AUC<sub>0–24</sub>/MIC ratio) >400 (assuming MIC ≤1 mg/L).</p></sec><sec><title>Results</title><p>Data of 42 patients from 26 ICUs were eligible for analysis. A total of 24 patients received vancomycin by continuous infusion (57%). Daily dosage of vancomycin was 27 mg/kg (interquartile range (IQR) 18 to 32), and not different between patients receiving intermittent or continuous infusion. Trough concentrations were highly variable (median 27, IQR 8 to 23 mg/L). Target trough concentrations were achieved in 57% of patients, but more frequently in patients receiving continuous infusion (71% versus 39%; <italic>P</italic> = 0.038). Also the target AUC<sub>0–24</sub>/MIC ratio was reached more frequently in patients receiving continuous infusion (88% versus 50%; <italic>P</italic> = 0.008). Multivariable logistic regression analysis with adjustment by the propensity score could not confirm continuous infusion as an independent predictor of an AUC<sub>0–24</sub>/MIC >400 (odds ratio (OR) 1.65, 95% confidence interval (CI) 0.2 to 12.0) or a C<sub>min</sub> ≥15 mg/L (OR 1.8, 95% CI 0.4 to 8.5).</p></sec><sec><title>Conclusions</title><p>This study demonstrated large interindividual variability in vancomycin pharmacokinetic and pharmacodynamic target attainment in ICU patients. These data suggests that a re-evaluation of current vancomycin dosing recommendations in critically ill patients is needed to more rapidly and consistently achieve sufficient vancomycin exposure.</p></sec></div></front><back><div1 type="bibliography"><listBibl><biblStruct><analytic><author><name sortKey="Boucher, H" uniqKey="Boucher H">H Boucher</name></author><author><name sortKey="Miller, Lg" uniqKey="Miller L">LG Miller</name></author><author><name sortKey="Razonable, Rr" uniqKey="Razonable R">RR Razonable</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Liu, C" uniqKey="Liu C">C Liu</name></author><author><name sortKey="Bayer, A" uniqKey="Bayer A">A Bayer</name></author><author><name sortKey="Cosgrove, Se" uniqKey="Cosgrove S">SE Cosgrove</name></author><author><name sortKey="Daum, Rs" uniqKey="Daum R">RS Daum</name></author><author><name sortKey="Fridkin, Sk" uniqKey="Fridkin S">SK Fridkin</name></author><author><name sortKey="Gorwitz, Rj" uniqKey="Gorwitz R">RJ Gorwitz</name></author><author><name sortKey="Kaplan, Sl" uniqKey="Kaplan S">SL Kaplan</name></author><author><name sortKey="Karchmer, Aw" uniqKey="Karchmer A">AW Karchmer</name></author><author><name sortKey="Levine, Dp" uniqKey="Levine D">DP Levine</name></author><author><name sortKey="Murray, Be" uniqKey="Murray B">BE Murray</name></author><author><name sortKey="Rybak, Mj" uniqKey="Rybak M">MJ Rybak</name></author><author><name sortKey="Talan, Da" uniqKey="Talan D">DA Talan</name></author><author><name sortKey="Chambers, Hf" uniqKey="Chambers H">HF Chambers</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Rybak, Mj" uniqKey="Rybak M">MJ Rybak</name></author><author><name sortKey="Lomaestro, Bm" uniqKey="Lomaestro B">BM Lomaestro</name></author><author><name sortKey="Rotschafer, Jc" uniqKey="Rotschafer J">JC Rotschafer</name></author><author><name sortKey="Moellering, Rc" uniqKey="Moellering R">RC Moellering</name></author><author><name sortKey="Craig, Wa" uniqKey="Craig W">WA Craig</name></author><author><name sortKey="Billeter, M" uniqKey="Billeter M">M Billeter</name></author><author><name sortKey="Dalovisio, Jr" uniqKey="Dalovisio J">JR Dalovisio</name></author><author><name sortKey="Levine, Dp" uniqKey="Levine D">DP Levine</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Moise Broder, Pa" uniqKey="Moise Broder P">PA Moise-Broder</name></author><author><name sortKey="Forrest, A" uniqKey="Forrest A">A Forrest</name></author><author><name sortKey="Birmingham, Mc" uniqKey="Birmingham M">MC Birmingham</name></author><author><name sortKey="Schentag, Jj" uniqKey="Schentag J">JJ Schentag</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Holmes, Ne" uniqKey="Holmes N">NE Holmes</name></author><author><name sortKey="Turnidge, Jd" uniqKey="Turnidge J">JD Turnidge</name></author><author><name sortKey="Munckhof, Wj" uniqKey="Munckhof W">WJ Munckhof</name></author><author><name sortKey="Robinson, Jo" uniqKey="Robinson J">JO Robinson</name></author><author><name sortKey="Korman, Tm" uniqKey="Korman T">TM Korman</name></author><author><name sortKey="O Sullivan, Mv" uniqKey="O Sullivan M">MV O'Sullivan</name></author><author><name sortKey="Anderson, Tl" uniqKey="Anderson T">TL Anderson</name></author><author><name sortKey="Roberts, Sa" uniqKey="Roberts S">SA Roberts</name></author><author><name sortKey="Warren, Sj" uniqKey="Warren S">SJ Warren</name></author><author><name sortKey="Gao, W" uniqKey="Gao W">W Gao</name></author><author><name sortKey="Howden, Bp" uniqKey="Howden B">BP Howden</name></author><author><name sortKey="Johnson, Pd" uniqKey="Johnson P">PD Johnson</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kullar, R" uniqKey="Kullar R">R Kullar</name></author><author><name sortKey="Davis, Sl" uniqKey="Davis S">SL Davis</name></author><author><name sortKey="Levine, Dp" uniqKey="Levine D">DP Levine</name></author><author><name sortKey="Rybak, Mj" uniqKey="Rybak M">MJ Rybak</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Roberts, Ja" uniqKey="Roberts J">JA Roberts</name></author><author><name sortKey="Lipman, J" uniqKey="Lipman J">J Lipman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Udy, Aa" uniqKey="Udy A">AA Udy</name></author><author><name sortKey="Roberts, Ja" uniqKey="Roberts J">JA Roberts</name></author><author><name sortKey="Lipman, J" uniqKey="Lipman J">J Lipman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Roberts, Ja" uniqKey="Roberts J">JA Roberts</name></author><author><name sortKey="Paul, Sk" uniqKey="Paul S">SK Paul</name></author><author><name sortKey="Akova, M" uniqKey="Akova M">M Akova</name></author><author><name sortKey="Bassetti, M" uniqKey="Bassetti M">M Bassetti</name></author><author><name sortKey="De Waele, Jj" uniqKey="De Waele J">JJ De Waele</name></author><author><name sortKey="Dimopoulos, G" uniqKey="Dimopoulos G">G Dimopoulos</name></author><author><name sortKey="Kaukonen, K M" uniqKey="Kaukonen K">K-M Kaukonen</name></author><author><name sortKey="Koulenti, D" uniqKey="Koulenti D">D Koulenti</name></author><author><name sortKey="Martin, C" uniqKey="Martin C">C Martin</name></author><author><name sortKey="Montravers, P" uniqKey="Montravers P">P Montravers</name></author><author><name sortKey="Rello, J" uniqKey="Rello J">J Rello</name></author><author><name sortKey="Rhodes, A" uniqKey="Rhodes A">A Rhodes</name></author><author><name sortKey="Starr, T" uniqKey="Starr T">T Starr</name></author><author><name sortKey="Wallis, Sc" uniqKey="Wallis S">SC Wallis</name></author><author><name sortKey="Lipman, J" uniqKey="Lipman J">J Lipman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Roberts, Dm" uniqKey="Roberts D">DM Roberts</name></author><author><name sortKey="Roberts, Ja" uniqKey="Roberts J">JA Roberts</name></author><author><name sortKey="Roberts, Ms" uniqKey="Roberts M">MS Roberts</name></author><author><name sortKey="Liu, X" uniqKey="Liu X">X Liu</name></author><author><name sortKey="Nair, P" uniqKey="Nair P">P Nair</name></author><author><name sortKey="Cole, L" uniqKey="Cole L">L Cole</name></author><author><name sortKey="Lipman, J" uniqKey="Lipman J">J Lipman</name></author><author><name sortKey="Bellomo, R" uniqKey="Bellomo R">R Bellomo</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Jamal, Ja" uniqKey="Jamal J">JA Jamal</name></author><author><name sortKey="Economou, Cj" uniqKey="Economou C">CJ Economou</name></author><author><name sortKey="Lipman, J" uniqKey="Lipman J">J Lipman</name></author><author><name sortKey="Roberts, Ja" uniqKey="Roberts J">JA Roberts</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Li, J" uniqKey="Li J">J Li</name></author><author><name sortKey="Udy, Aa" uniqKey="Udy A">AA Udy</name></author><author><name sortKey="Kirkpatrick, Cm" uniqKey="Kirkpatrick C">CM Kirkpatrick</name></author><author><name sortKey="Lipman, J" uniqKey="Lipman J">J Lipman</name></author><author><name sortKey="Roberts, Ja" uniqKey="Roberts J">JA Roberts</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Roberts, Ja" uniqKey="Roberts J">JA Roberts</name></author><author><name sortKey="Taccone, Fs" uniqKey="Taccone F">FS Taccone</name></author><author><name sortKey="Udy, Aa" uniqKey="Udy A">AA Udy</name></author><author><name sortKey="Vincent, Jl" uniqKey="Vincent J">JL Vincent</name></author><author><name sortKey="Jacobs, F" uniqKey="Jacobs F">F Jacobs</name></author><author><name sortKey="Lipman, J" uniqKey="Lipman J">J Lipman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Udy, Aa" uniqKey="Udy A">AA Udy</name></author><author><name sortKey="Covajes, C" uniqKey="Covajes C">C Covajes</name></author><author><name sortKey="Taccone, Fs" uniqKey="Taccone F">FS Taccone</name></author><author><name sortKey="Jacobs, F" uniqKey="Jacobs F">F Jacobs</name></author><author><name sortKey="Vincent, Jl" uniqKey="Vincent J">JL Vincent</name></author><author><name sortKey="Lipman, J" uniqKey="Lipman J">J Lipman</name></author><author><name sortKey="Roberts, Ja" uniqKey="Roberts J">JA Roberts</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zelenitsky, S" uniqKey="Zelenitsky S">S Zelenitsky</name></author><author><name sortKey="Rubinstein, E" uniqKey="Rubinstein E">E Rubinstein</name></author><author><name sortKey="Ariano, R" uniqKey="Ariano R">R Ariano</name></author><author><name sortKey="Iacovides, H" uniqKey="Iacovides H">H Iacovides</name></author><author><name sortKey="Dodek, P" uniqKey="Dodek P">P Dodek</name></author><author><name sortKey="Mirzanejad, Y" uniqKey="Mirzanejad Y">Y Mirzanejad</name></author><author><name sortKey="Kumar, A" uniqKey="Kumar A">A Kumar</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Brown, J" uniqKey="Brown J">J Brown</name></author><author><name sortKey="Brown, K" uniqKey="Brown K">K Brown</name></author><author><name sortKey="Forrest, A" uniqKey="Forrest A">A Forrest</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Roberts, Ja" uniqKey="Roberts J">JA Roberts</name></author><author><name sortKey="De Waele, Jj" uniqKey="De Waele J">JJ De Waele</name></author><author><name sortKey="Dimopoulos, G" uniqKey="Dimopoulos G">G Dimopoulos</name></author><author><name sortKey="Koulenti, D" uniqKey="Koulenti D">D Koulenti</name></author><author><name sortKey="Martin, C" uniqKey="Martin C">C Martin</name></author><author><name sortKey="Montravers, P" uniqKey="Montravers P">P Montravers</name></author><author><name sortKey="Rello, J" uniqKey="Rello J">J Rello</name></author><author><name sortKey="Rhodes, A" uniqKey="Rhodes A">A Rhodes</name></author><author><name sortKey="Starr, T" uniqKey="Starr T">T Starr</name></author><author><name sortKey="Wallis, Sc" uniqKey="Wallis S">SC Wallis</name></author><author><name sortKey="Lipman, J" uniqKey="Lipman J">J Lipman</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Matzke, Gr" uniqKey="Matzke G">GR Matzke</name></author><author><name sortKey="Mcgory, Rw" uniqKey="Mcgory R">RW McGory</name></author><author><name sortKey="Halstenson, Ce" uniqKey="Halstenson C">CE Halstenson</name></author><author><name sortKey="Keane, Wf" uniqKey="Keane W">WF Keane</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Taccone, Fs" uniqKey="Taccone F">FS Taccone</name></author><author><name sortKey="Laterre, Pf" uniqKey="Laterre P">PF Laterre</name></author><author><name sortKey="Spapen, H" uniqKey="Spapen H">H Spapen</name></author><author><name sortKey="Dugernier, T" uniqKey="Dugernier T">T Dugernier</name></author><author><name sortKey="Delattre, I" uniqKey="Delattre I">I Delattre</name></author><author><name sortKey="Layeux, B" uniqKey="Layeux B">B Layeux</name></author><author><name sortKey="De Backer, D" uniqKey="De Backer D">D De Backer</name></author><author><name sortKey="Wittebole, X" uniqKey="Wittebole X">X Wittebole</name></author><author><name sortKey="Wallemacq, P" uniqKey="Wallemacq P">P Wallemacq</name></author><author><name sortKey="Vincent, Jl" uniqKey="Vincent J">JL Vincent</name></author><author><name sortKey="Jacobs, F" uniqKey="Jacobs F">F Jacobs</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Van Zanten, Ar" uniqKey="Van Zanten A">AR van Zanten</name></author><author><name sortKey="Polderman, Kh" uniqKey="Polderman K">KH Polderman</name></author><author><name sortKey="Van Geijlswijk, Im" uniqKey="Van Geijlswijk I">IM van Geijlswijk</name></author><author><name sortKey="Van Der Meer, Gy" uniqKey="Van Der Meer G">GY van der Meer</name></author><author><name sortKey="Schouten, Ma" uniqKey="Schouten M">MA Schouten</name></author><author><name sortKey="Girbes, Ar" uniqKey="Girbes A">AR Girbes</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Taccone, Fs" uniqKey="Taccone F">FS Taccone</name></author><author><name sortKey="Laterre, Pf" uniqKey="Laterre P">PF Laterre</name></author><author><name sortKey="Dugernier, T" uniqKey="Dugernier T">T Dugernier</name></author><author><name sortKey="Spapen, H" uniqKey="Spapen H">H Spapen</name></author><author><name sortKey="Delattre, I" uniqKey="Delattre I">I Delattre</name></author><author><name sortKey="Wittebole, X" uniqKey="Wittebole X">X Wittebole</name></author><author><name sortKey="De Backer, D" uniqKey="De Backer D">D De Backer</name></author><author><name sortKey="Layeux, B" uniqKey="Layeux B">B Layeux</name></author><author><name sortKey="Wallemacq, P" uniqKey="Wallemacq P">P Wallemacq</name></author><author><name sortKey="Vincent, Jl" uniqKey="Vincent J">JL Vincent</name></author><author><name sortKey="Jacobs, F" uniqKey="Jacobs F">F Jacobs</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Roberts, Ja" uniqKey="Roberts J">JA Roberts</name></author><author><name sortKey="Lipman, J" uniqKey="Lipman J">J Lipman</name></author><author><name sortKey="Blot, S" uniqKey="Blot S">S Blot</name></author><author><name sortKey="Rello, J" uniqKey="Rello J">J Rello</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Blot, S" uniqKey="Blot S">S Blot</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wysocki, M" uniqKey="Wysocki M">M Wysocki</name></author><author><name sortKey="Delatour, F" uniqKey="Delatour F">F Delatour</name></author><author><name sortKey="Faurisson, F" uniqKey="Faurisson F">F Faurisson</name></author><author><name sortKey="Rauss, A" uniqKey="Rauss A">A Rauss</name></author><author><name sortKey="Pean, Y" uniqKey="Pean Y">Y Pean</name></author><author><name sortKey="Misset, B" uniqKey="Misset B">B Misset</name></author><author><name sortKey="Thomas, F" uniqKey="Thomas F">F Thomas</name></author><author><name sortKey="Timsit, Jf" uniqKey="Timsit J">JF Timsit</name></author><author><name sortKey="Similowski, T" uniqKey="Similowski T">T Similowski</name></author><author><name sortKey="Mentec, H" uniqKey="Mentec H">H Mentec</name></author><author><name sortKey="Mier, L" uniqKey="Mier L">L Mier</name></author><author><name sortKey="Dreyfuss, D" uniqKey="Dreyfuss D">D Dreyfuss</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Akers, Ks" uniqKey="Akers K">KS Akers</name></author><author><name sortKey="Cota, Jm" uniqKey="Cota J">JM Cota</name></author><author><name sortKey="Chung, Kk" uniqKey="Chung K">KK Chung</name></author><author><name sortKey="Renz, Em" uniqKey="Renz E">EM Renz</name></author><author><name sortKey="Mende, K" uniqKey="Mende K">K Mende</name></author><author><name sortKey="Murray, Ck" uniqKey="Murray C">CK Murray</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Vuagnat, A" uniqKey="Vuagnat A">A Vuagnat</name></author><author><name sortKey="Stern, R" uniqKey="Stern R">R Stern</name></author><author><name sortKey="Lotthe, A" uniqKey="Lotthe A">A Lotthe</name></author><author><name sortKey="Schuhmacher, H" uniqKey="Schuhmacher H">H Schuhmacher</name></author><author><name sortKey="Duong, M" uniqKey="Duong M">M Duong</name></author><author><name sortKey="Hoffmeyer, P" uniqKey="Hoffmeyer P">P Hoffmeyer</name></author><author><name sortKey="Bernard, L" uniqKey="Bernard L">L Bernard</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Rello, J" uniqKey="Rello J">J Rello</name></author><author><name sortKey="Sole Violan, J" uniqKey="Sole Violan J">J Sole-Violan</name></author><author><name sortKey="Sa Borges, M" uniqKey="Sa Borges M">M Sa-Borges</name></author><author><name sortKey="Garnacho Montero, J" uniqKey="Garnacho Montero J">J Garnacho-Montero</name></author><author><name sortKey="Munoz, E" uniqKey="Munoz E">E Munoz</name></author><author><name sortKey="Sirgo, G" uniqKey="Sirgo G">G Sirgo</name></author><author><name sortKey="Olona, M" uniqKey="Olona M">M Olona</name></author><author><name sortKey="Diaz, E" uniqKey="Diaz E">E Diaz</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="De Waele, Jj" uniqKey="De Waele J">JJ De Waele</name></author><author><name sortKey="Danneels, I" uniqKey="Danneels I">I Danneels</name></author><author><name sortKey="Depuydt, P" uniqKey="Depuydt P">P Depuydt</name></author><author><name sortKey="Decruyenaere, J" uniqKey="Decruyenaere J">J Decruyenaere</name></author><author><name sortKey="Bourgeois, M" uniqKey="Bourgeois M">M Bourgeois</name></author><author><name sortKey="Hoste, E" uniqKey="Hoste E">E Hoste</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Golenia, Bs" uniqKey="Golenia B">BS Golenia</name></author><author><name sortKey="Levine, Ar" uniqKey="Levine A">AR Levine</name></author><author><name sortKey="Moawad, Im" uniqKey="Moawad I">IM Moawad</name></author><author><name sortKey="Yeh, Dd" uniqKey="Yeh D">DD Yeh</name></author><author><name sortKey="Arpino, Pa" uniqKey="Arpino P">PA Arpino</name></author></analytic></biblStruct><biblStruct></biblStruct></listBibl></div1></back></TEI><pmc article-type="research-article" xml:lang="en"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Crit Care</journal-id><journal-id journal-id-type="iso-abbrev">Crit Care</journal-id><journal-title-group><journal-title>Critical Care</journal-title></journal-title-group><issn pub-type="ppub">1364-8535</issn><issn pub-type="epub">1466-609X</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24887569</article-id><article-id pub-id-type="pmc">4075416</article-id><article-id pub-id-type="publisher-id">cc13874</article-id><article-id pub-id-type="doi">10.1186/cc13874</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Does contemporary vancomycin dosing achieve therapeutic targets in a heterogeneous clinical cohort of critically ill patients? Data from the multinational DALI study</article-title></title-group><contrib-group><contrib contrib-type="author" id="A1"><name><surname>Blot</surname><given-names>Stijn</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>stijn.blot@UGent.be</email></contrib><contrib contrib-type="author" id="A2"><name><surname>Koulenti</surname><given-names>Despoina</given-names></name><xref ref-type="aff" rid="I2">2</xref><xref ref-type="aff" rid="I3">3</xref><xref ref-type="aff" rid="I4">4</xref><email>deskogr@yahoo.gr</email></contrib><contrib contrib-type="author" id="A3"><name><surname>Akova</surname><given-names>Murat</given-names></name><xref ref-type="aff" rid="I5">5</xref><email>makova@hacettepe.edu.tr</email></contrib><contrib contrib-type="author" id="A4"><name><surname>Bassetti</surname><given-names>Matteo</given-names></name><xref ref-type="aff" rid="I6">6</xref><email>mattba@tin.it</email></contrib><contrib contrib-type="author" id="A5"><name><surname>De Waele</surname><given-names>Jan J</given-names></name><xref ref-type="aff" rid="I7">7</xref><email>Jan.DeWaele@UGent.be</email></contrib><contrib contrib-type="author" id="A6"><name><surname>Dimopoulos</surname><given-names>George</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>gdimop@med.uoa.gr</email></contrib><contrib contrib-type="author" id="A7"><name><surname>Kaukonen</surname><given-names>Kirsi-Maija</given-names></name><xref ref-type="aff" rid="I8">8</xref><xref ref-type="aff" rid="I9">9</xref><email>maija.kaukonen@monash.edu</email></contrib><contrib contrib-type="author" id="A8"><name><surname>Martin</surname><given-names>Claude</given-names></name><xref ref-type="aff" rid="I10">10</xref><xref ref-type="aff" rid="I11">11</xref><email>claude.martin@mail.ap-hm.fr</email></contrib><contrib contrib-type="author" id="A9"><name><surname>Montravers</surname><given-names>Philippe</given-names></name><xref ref-type="aff" rid="I12">12</xref><email>philippe.montravers@bch.ap-hop-paris.fr</email></contrib><contrib contrib-type="author" id="A10"><name><surname>Rello</surname><given-names>Jordi</given-names></name><xref ref-type="aff" rid="I13">13</xref><email>jrello@crips.es</email></contrib><contrib contrib-type="author" id="A11"><name><surname>Rhodes</surname><given-names>Andrew</given-names></name><xref ref-type="aff" rid="I14">14</xref><email>andrewrhodes@nhs.net</email></contrib><contrib contrib-type="author" id="A12"><name><surname>Starr</surname><given-names>Therese</given-names></name><xref ref-type="aff" rid="I2">2</xref><xref ref-type="aff" rid="I3">3</xref><email>Therese.Starr@health.qld.gov.au</email></contrib><contrib contrib-type="author" id="A13"><name><surname>Wallis</surname><given-names>Steven C</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>s.wallis@uq.edu.au</email></contrib><contrib contrib-type="author" id="A14"><name><surname>Lipman</surname><given-names>Jeffrey</given-names></name><xref ref-type="aff" rid="I2">2</xref><xref ref-type="aff" rid="I3">3</xref><email>j.lipman@uq.edu.au</email></contrib><contrib contrib-type="author" corresp="yes" id="A15"><name><surname>Roberts</surname><given-names>Jason A</given-names></name><xref ref-type="aff" rid="I2">2</xref><xref ref-type="aff" rid="I3">3</xref><email>j.roberts2@uq.edu.au</email></contrib></contrib-group><aff id="I1"><label>1</label>Department of Internal Medicine, Faculty of Medicine & Health Science, Ghent University, Sint-Pietersnieuwstraat 25, 9000 Ghent, Belgium</aff><aff id="I2"><label>2</label>Burns Trauma and Critical Care Research Centre, The University of Queensland, Butterfield Street, Herston, Brisbane, QLD 4029, Australia</aff><aff id="I3"><label>3</label>Royal Brisbane and Women’s Hospital, Butterfield Street, Herston, Brisbane, QLD 4006, Australia</aff><aff id="I4"><label>4</label>Attikon University Hospital, 1, Rimini Street, Haidari, 124 62 Athens, Greece</aff><aff id="I5"><label>5</label>Hacettepe University, School of Medicine, 06100 Sıhhiye, Ankara, Turkey</aff><aff id="I6"><label>6</label>Azienda Ospedaliera Universitaria Santa Maria della Misericordia, Piazzale Santa Maria della Misericordia, 15, 33100 Udine, Italy</aff><aff id="I7"><label>7</label>Ghent University Hospital, De Pintelaan 185, 9000 Ghent, Belgium</aff><aff id="I8"><label>8</label>Helsinki University Central Hospital, Haartmaninkatu 3, 00029 Helsinki, Uusimaa, Finland</aff><aff id="I9"><label>9</label>Australian and New Zealand Intensive Care Research Centre (ANZIC RC), Department of Epidemiology and Preventive Medicine, Monash University, 99 Commercial Road, Melbourne, VIC 3004, Australia</aff><aff id="I10"><label>10</label>Hospital Nord, Chemin des Bourrely, 13015 Marseille, France</aff><aff id="I11"><label>11</label>AzuRea Group, France</aff><aff id="I12"><label>12</label>Centre Hospitalier Universitaire Bichat-Claude Bernard, AP-HP, Université Paris VII, 46 Rue Henri Huchard, 75018 Paris, France</aff><aff id="I13"><label>13</label>CIBERES, Vall d'Hebron Institute of Research, Universitat Autonoma de Barcelona, Passeig de la Vall d’Hebron, 119-129, 08035 Barcelona, Spain</aff><aff id="I14"><label>14</label>St George’s Healthcare NHS Trust and St George’s University of London, Cranmer Terrace, London SW17 0RE, UK</aff><pub-date pub-type="ppub"><year>2014</year></pub-date><pub-date pub-type="epub"><day>15</day><month>5</month><year>2014</year></pub-date><volume>18</volume><issue>3</issue><fpage>R99</fpage><lpage>R99</lpage><history><date date-type="received"><day>28</day><month>11</month><year>2013</year></date><date date-type="accepted"><day>29</day><month>4</month><year>2014</year></date></history><permissions><copyright-statement>Copyright © 2014 Blot et al.; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2014</copyright-year><copyright-holder>Blot et al.; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="http://ccforum.com/content/18/3/R99"></self-uri><abstract><sec><title>Introduction</title><p>The objective of this study was to describe the pharmacokinetics of vancomycin in ICU patients and to examine whether contemporary antibiotic dosing results in concentrations that have been associated with favourable response.</p></sec><sec><title>Methods</title><p>The Defining Antibiotic Levels in Intensive Care (DALI) study was a prospective, multicentre pharmacokinetic point-prevalence study. Antibiotic dosing was as per the treating clinician either by intermittent bolus or continuous infusion. Target trough concentration was defined as ≥15 mg/L and target pharmacodynamic index was defined as an area under the concentration-time curve over a 24-hour period divided by the minimum inhibitory concentration of the suspected bacteria (AUC<sub>0–24</sub>/MIC ratio) >400 (assuming MIC ≤1 mg/L).</p></sec><sec><title>Results</title><p>Data of 42 patients from 26 ICUs were eligible for analysis. A total of 24 patients received vancomycin by continuous infusion (57%). Daily dosage of vancomycin was 27 mg/kg (interquartile range (IQR) 18 to 32), and not different between patients receiving intermittent or continuous infusion. Trough concentrations were highly variable (median 27, IQR 8 to 23 mg/L). Target trough concentrations were achieved in 57% of patients, but more frequently in patients receiving continuous infusion (71% versus 39%; <italic>P</italic> = 0.038). Also the target AUC<sub>0–24</sub>/MIC ratio was reached more frequently in patients receiving continuous infusion (88% versus 50%; <italic>P</italic> = 0.008). Multivariable logistic regression analysis with adjustment by the propensity score could not confirm continuous infusion as an independent predictor of an AUC<sub>0–24</sub>/MIC >400 (odds ratio (OR) 1.65, 95% confidence interval (CI) 0.2 to 12.0) or a C<sub>min</sub> ≥15 mg/L (OR 1.8, 95% CI 0.4 to 8.5).</p></sec><sec><title>Conclusions</title><p>This study demonstrated large interindividual variability in vancomycin pharmacokinetic and pharmacodynamic target attainment in ICU patients. These data suggests that a re-evaluation of current vancomycin dosing recommendations in critically ill patients is needed to more rapidly and consistently achieve sufficient vancomycin exposure.</p></sec></abstract></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Methicillin-resistant <italic>Staphylococcus aureus</italic> (MRSA) has become a major pathogen in severe healthcare-associated infections [<xref ref-type="bibr" rid="B1">1</xref>]. In the past decades, the anti-MRSA armamentarium has broadened. Still, vancomycin remains the most common first-line option for treating severe infections with parenteral therapy [<xref ref-type="bibr" rid="B2">2</xref>]. Achievement of pharmacokinetic/pharmacodynamic (PK/PD) indices associated with maximal bacterial kill is recommended to increase the likelihood of clinical cure. To achieve target serum concentrations in life-threatening infections such as sepsis, infective endocarditis, osteomyelitis and hospital-acquired pneumonia, current guidelines recommend trough serum concentrations of vancomycin (C<sub>min</sub>) ranging 15 to 20 mg/L [<xref ref-type="bibr" rid="B3">3</xref>]. Such serum concentrations should achieve an area under the concentration-time curve over a 24-hour period divided by the minimum inhibitory concentration of the suspected bacteria (AUC<sub>0–24</sub>/MIC ratio) of >400 (assuming an MIC ≤1 mg/L). This threshold was significantly associated with favourable clinical and bacteriological outcomes in patients with lower respiratory tract infections and therefore generally accepted as the appropriate PK/PD target [<xref ref-type="bibr" rid="B4">4</xref>]. Other investigators confirmed that an AUC<sub>0–24</sub>/MIC ratio for optimizing clinical outcomes should be at least 400 [<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B6">6</xref>].</p><p>In critically ill patients with severe sepsis or septic shock however, target concentrations may be difficult to achieve due to the increased distribution volume and the presence of augmented renal clearance (ARC) [<xref ref-type="bibr" rid="B7">7</xref>-<xref ref-type="bibr" rid="B9">9</xref>]. These factors may lead to reduced trough concentrations and underdosing, leading to inadequate bacterial killing and possible treatment failure. Moreover, insufficient dosing may facilitate development of multidrug resistance. As vancomycin is renally cleared and distributes widely throughout the body, its pharmacokinetics may be altered from the pathophysiological alterations inherent to sepsis. Furthermore, these factors imply great interindividual variability in pharmacokinetics complicating accurate prediction of serum concentrations in septic patients.</p><p>Alternatively, the course of ICU patients may be complicated by acute kidney injury (AKI), in which case decreased vancomycin clearance and subsequent increased trough concentrations may cause toxicity. Should AKI worsen, renal replacement therapy (RRT) may be required with drug clearance varying according to mode of RRT, dose of RRT delivered, filter material and surface area, and blood flow rate [<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B11">11</xref>]. As such, factors that may lead to underdosing as well as overdosing are to be considered. The above-mentioned conditions call for an altered dosing approach in critically ill patients compared with mild-to-moderately ill patients [<xref ref-type="bibr" rid="B12">12</xref>-<xref ref-type="bibr" rid="B14">14</xref>]. Several investigators reported on pharmacokinetics of vancomycin in critically ill patients [<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B15">15</xref>,<xref ref-type="bibr" rid="B16">16</xref>] but most studies are single centre designs and there is no insight in current practice - and therefore in pharmacokinetics variability - across ICUs.</p><p>The objective of this study was to describe the pharmacokinetics of vancomycin in critically ill patients and to examine whether contemporary antibiotic dosing for ICU patients achieves concentrations that are associated with favourable response in previous reports. We hypothesised that vancomycin target trough concentrations and AUC<sub>0–24</sub>/MIC are frequently not achieved and demonstrate considerable variability in critically ill patients. Furthermore, we investigated the role of continuous infusion of vancomycin. We also studied factors associated with favourable pharmacokinetic outcome (trough concentration ≥15 mg/L and AUC<sub>0–24</sub>/MIC ratio >400).</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Study design</title><p>The Defining Antibiotic Levels in Intensive Care (DALI) study was a prospective, multicentre pharmacokinetic point-prevalence study. For detailed information on methods we refer the reader to the protocol of DALI study that has been previously published [<xref ref-type="bibr" rid="B17">17</xref>]. In this secondary study patients receiving intravenous vancomycin, intermittently or continuously, were analysed.</p></sec><sec><title>Patients</title><p>Critically ill adult patients were all identified for participation by clinical ICU staff on the Monday of the nominated sampling week, with blood sampling and data collection occurring throughout that week. Ethical approval to participate in this study was obtained at all participating centres and informed consent was obtained from each patient or their legally authorised representative. The lead site was The University of Queensland, Australia with ethical approval granted by the Medical Research Ethics Committee (no. 201100283, May 2011). The contributing authors are listed in Additional file <xref ref-type="supplementary-material" rid="S1">1</xref> and the sites and their ethical approval bodies are listed in Additional file <xref ref-type="supplementary-material" rid="S2">2</xref>.</p></sec><sec><title>Intervention</title><p>Antibiotic dosing was as per the treating clinician and therapy could be administered by either intravenous intermittent or continuous infusion. Each patient had two blood samples taken: for intermittent administration of vancomycin, blood sample A was a mid-dose blood sample at 50% of the way through a dosing interval and blood sample B was a pre-dose concentration at the end of a dosing interval (within 30 minutes of the next dose), while for continuous administration sample A was at any time and sample B was >6 hours after sample A. The observed concentrations were then interpreted in relation to a presumed MIC of 1 mg/L.</p></sec><sec><title>Data collection</title><p>Data collection was performed by trained staff at each participating centre and entered onto a case report form (CRF). Various demographic and clinical data were collected, including age, gender, height, weight, admission diagnosis, presence of extracorporeal circuits (for example RRT), clinical outcome of infection, presence/absence of surgery within previous 24 hours, and mortality at 30 days. Also, organ function data (including renal function - serum creatinine concentration during studied dosing interval; eight-hour urinary creatinine clearance (where available), fluid balance for total length of stay and previous 24 hours), antibiotic dosing (dose and frequency, time of dosing and sampling, day of antibiotic therapy), and infection data (including known or presumed pathogen) were collected.</p><p>Antibiotic dosing data including the dose, infusion duration, frequency of administration, the time of dosing and sampling and the day of antibiotic therapy were collected. All data were collated by the coordinating centre (Burns, Trauma and Critical Care Research Centre, The University of Queensland, Australia).</p></sec><sec><title>Bioanalysis</title><p>Blood samples were processed and stored per protocol to maintain integrity. Vancomycin concentrations in serum were determined by a validated chromatographic assay method on an Applied Biosystems API2000 mass spectrometer (Applied Biosystems, Foster City, CA, USA) with Shimadzu high-performance liquid chromatography (HPLC) system (Shimadzu Corp., Kyoto, Japan). The stationary phase was a Waters X-Terra C18 column (5 μm, 150 × 2.1 mm) (Waters Corp., Milford, MA, USA) and the mobile phase was a gradient (between 20% and 95% organic) of methanol containing 10 mM heptafluorobutyric acid (HFBA) with 0.1% formic acid containing 10 mM HFBA. Vancomycin and the internal standard (tobramycin) were detected using multiple reaction monitoring (MRM) scans in positive ion detection mode with electrospray ionisation (ESI) sample introduction. Vancomycin standards and quality controls were prepared in serum. One hundred microlitres of sample was mixed with the internal standard and the sample then de-proteinated with acetonitrile and lipids removed with dichloromethane before injection. The method fitted a quadratic regression profile from 0.1 to 100 μg/mL. Accuracy and precision were determined from quality controls at high, medium and low concentrations and were within 10% at all levels. These methods are in accordance with the US Food and Drug Administration’s guidance for industry on bioanalysis [<xref ref-type="bibr" rid="B18">18</xref>].</p></sec><sec><title>Pharmacokinetic analyses</title><p>The pharmacokinetic values were calculated using non-compartmental methods. The apparent terminal elimination rate constant (kel) was determined from log-linear least squares regression analysis of concentrations from sample A and B. For intermittent infusions, the maximum concentration for the dosing period (C<sub>max</sub>) was calculated using the following equation:</p><p><disp-formula><mml:math id="M1" name="cc13874-i1" overflow="scroll"><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="italic">C</mml:mi></mml:mrow><mml:mrow><mml:mtext>max</mml:mtext></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="italic">C</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="true">/</mml:mo><mml:mfenced open="(" close=")"><mml:mrow><mml:mn>1</mml:mn><mml:mo>–</mml:mo><mml:msup><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="normal">e</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mi mathvariant="normal">kel</mml:mi><mml:mo>.</mml:mo></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:mi mathvariant="normal">τ</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:mfenced></mml:mrow></mml:math></disp-formula></p><p>Where C<sub>0</sub> is the concentration at sample A and τ is the dosing interval in hours. The minimum concentration for the dosing period (C<sub>min</sub>) was the observed value. Half-life (T<sub>1/2</sub>) was calculated as ln(2)/<sub>z</sub>. The area under the concentration time curve from 0 to 12 hours (AUC<sub>0–12</sub>) was calculated using the linear trapezoidal rule with the derived C<sub>max</sub> estimate. The AUC from 0 to 24 hours (AUC<sub>0–24</sub>) was calculated using a doubling of AUC<sub>0–12</sub> with pharmacokinetic steady-state assumed for all patients. For patients receiving continuous infusion, the AUC<sub>0–24</sub> was calculated using the average of concentrations for sample A and B multiplied by 24 hours. Vancomycin clearance (CL) was calculated using the equation dose/AUC<sub>0–12</sub>.</p><p>The AUC<sub>0–24</sub>/MIC ratio was calculated by dividing the AUC<sub>0–24</sub> by MICs 0.5, 1 and 2 mg/L.</p></sec><sec><title>Outcome variables</title><p>Vancomycin trough concentrations and AUC<sub>0–24</sub>/MIC ratios are the main PK/PD variables. The target trough concentration is defined as ≥15 mg/L and the target AUC<sub>0–24</sub>/MIC ratio is defined as >400.</p></sec><sec><title>Statistical analyses</title><p>Basic statistics on demographic, clinical and PK/PD related data were presented by number (%), median [1<sup>st</sup>-3<sup>rd</sup> quartile] or mean (standard deviation (SD)) as appropriate. Chi-square and Mann-Whitney <italic>U</italic> test were used as appropriate. Logistic regression analysis was used to assess unadjusted associations with the target PD index (AUC<sub>0–24</sub>/MIC ratio >400) or target trough concentration (≥15 mg/L) and independent variables. Various clinical and demographic factors were evaluated for entering into the model. Multivariable logistic regression was used to assess relationships between continuous infusion of vancomycin and the target PD index. In these analyses adjustment for covariates was obtained by means of a propensity score estimated for each subject on basis of a logistic regression of treatment (continuous or intermittent infusion) received on covariates. The propensity score represents a single variable reflecting the effect of the covariants on the probability of receiving continuous infusion. It summarises covariates with a statistical or plausible relationship with continuous infusion therapy or serum concentrations. Covariates used in the final propensity model were age, gender, sequential organ failure assessment (SOFA) score, RRT, fluid balance, vancomycin dose (mg/kg/24 h), infection source, and number of days on therapy. The area under the curve, representing the probability that the patient would receive continuous infusion based on the variables included, was 0.82 (95% confidence interval (CI) 0.68 to 0.96). Results of the regression analyses are reported as odds ratios (OR) and 95% CI. The Hosmer-Lemeshow test was used to assess whether or not the observed event rates match expected event rates in subgroups of the model population. Statistical significance was defined as <italic>P</italic> <0.05.</p></sec></sec><sec sec-type="results"><title>Results</title><p>Vancomycin blood samples were collected from 45 critically ill patients. Three patients were excluded as their samples were not viable. As such, the study sample consisted of 42 study subjects from 26 ICUs of eight countries (Andorra, Belgium, Spain, UK, Greece, Italy, Portugal, Turkey). Demographic data, disease severity, and renal function are described in Table <xref ref-type="table" rid="T1">1</xref>. Data are presented for patients receiving intermittent versus continuous vancomycin therapy. Vancomycin was given empirically in 31 patients (73.8%). Therapy was targeted in only 11 patients. MICs for isolated <italic>Staphylococcus</italic> spp. were only reported in two cases (both MIC 1 mg/L).</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p><bold>Characteristics of 42 critically ill patients receiving vancomycin therapy</bold>, <bold>stratified for intermittent dosing or continuous infusion</bold></p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"></col><col align="center"></col><col align="center"></col><col align="center"></col><col align="center"></col></colgroup><thead valign="top"><tr><th align="left"><bold>Characteristic</bold></th><th align="center"><bold>All patients (n = 42)</bold></th><th align="center"><bold>Intermittent dosing (n = 18)</bold></th><th align="center"><bold>Continuous infusion (n = 24)</bold></th><th align="center"><bold><italic>P</italic></bold><sup><bold>*</bold></sup></th></tr></thead><tbody valign="top"><tr><td align="left" valign="bottom">Age (years)<hr></hr></td><td align="center" valign="bottom">58 [45 <bold>-</bold> 66]<hr></hr></td><td align="center" valign="bottom">58 [32 <bold>-</bold> 79]<hr></hr></td><td align="center" valign="bottom">58 [45 <bold>-</bold> 66]<hr></hr></td><td align="center" valign="bottom">0.755<hr></hr></td></tr><tr><td align="left" valign="bottom">Male sex<hr></hr></td><td align="center" valign="bottom">27 (64.3)<hr></hr></td><td align="center" valign="bottom">13 (72.2)<hr></hr></td><td align="center" valign="bottom">14 (58.3)<hr></hr></td><td align="center" valign="bottom">0.353<hr></hr></td></tr><tr><td align="left" valign="bottom">Weight (kg)<hr></hr></td><td align="center" valign="bottom">70 [61 <bold>-</bold> 85]<hr></hr></td><td align="center" valign="bottom">75 [65 <bold>-</bold> 88]<hr></hr></td><td align="center" valign="bottom">70 [61 <bold>-</bold> 85]<hr></hr></td><td align="center" valign="bottom">0.350<hr></hr></td></tr><tr><td align="left" valign="bottom">APACHE II score<hr></hr></td><td align="center" valign="bottom">16 [13 <bold>-</bold> 25]<hr></hr></td><td align="center" valign="bottom">17 [14 <bold>-</bold> 27]<hr></hr></td><td align="center" valign="bottom">16 [13 <bold>-</bold> 25]<hr></hr></td><td align="center" valign="bottom">0.920<hr></hr></td></tr><tr><td align="left" valign="bottom">SOFA score<hr></hr></td><td align="center" valign="bottom">6 [3 <bold>-</bold> 9]<hr></hr></td><td align="center" valign="bottom">5 [3 <bold>-</bold> 6]<hr></hr></td><td align="center" valign="bottom">6 [3 <bold>-</bold> 9]<hr></hr></td><td align="center" valign="bottom">0.595<hr></hr></td></tr><tr><td align="left" valign="bottom">Serum creatinine concentration (μmol/L)<hr></hr></td><td align="center" valign="bottom">65 [51 <bold>-</bold> 113]<hr></hr></td><td align="center" valign="bottom">64 [52 <bold>-</bold> 91]<hr></hr></td><td align="center" valign="bottom">74 [44 <bold>-</bold> 129]<hr></hr></td><td align="center" valign="bottom">0.751<hr></hr></td></tr><tr><td align="left" valign="bottom">Urinary creatinine clearance (mL/min.)<hr></hr></td><td align="center" valign="bottom">85 [60 <bold>-</bold> 106]<hr></hr></td><td align="center" valign="bottom">72 [20 <bold>-</bold> 90]<hr></hr></td><td align="center" valign="bottom">101 [74 <bold>-</bold> 167]<hr></hr></td><td align="center" valign="bottom">0.198<hr></hr></td></tr><tr><td align="left" valign="bottom">Renal replacement therapy<hr></hr></td><td align="center" valign="bottom">9 (21.4)<hr></hr></td><td align="center" valign="bottom">1 (5.6)<hr></hr></td><td align="center" valign="bottom">8 (33.3)<hr></hr></td><td align="center" valign="bottom">NA<hr></hr></td></tr><tr><td align="left" valign="bottom"> Intermittent hemodialysis<hr></hr></td><td align="center" valign="bottom">2 (4.8)<hr></hr></td><td align="center" valign="bottom">0<hr></hr></td><td align="center" valign="bottom">2<hr></hr></td><td align="center" valign="bottom"> <hr></hr></td></tr><tr><td align="left"> Continuous renal replacement therapy</td><td align="center">7 (16.7)</td><td align="center">1</td><td align="center">6</td><td align="center"> </td></tr></tbody></table><table-wrap-foot><p>Data are described as median [1<sup>st</sup> - 3<sup>rd</sup> quartile] or n (%). <sup>*</sup>Indicates difference between intermittent dosing and continuous infusion of vancomycin. APACHE II, acute physiology and chronic health evaluation II; SOFA, sequential organ failure assessment; NA, not applicable as the expected count in at least one cell is less than 5.</p></table-wrap-foot></table-wrap><p>Data on dosing, pharmacokinetics and PK/PD are reported in Table <xref ref-type="table" rid="T2">2</xref>. Twenty-four patients received vancomycin by continuous infusion (57.1%). The average daily dosage of vancomycin was 27 (SD 13) mg/kg and was not different between patients in the continuous infusion and intermittent dosing group. No difference was observed in daily dosing between patients receiving RRT or with different glomerular filtration rates (GFRs) (Figure <xref ref-type="fig" rid="F1">1</xref>) (<italic>P</italic> = 0.359).</p><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Pharmacokinetic parameters and PK/PD target attainment of vancomycin in critically ill patients</p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"></col><col align="center"></col><col align="center"></col><col align="center"></col><col align="center"></col></colgroup><thead valign="top"><tr><th align="left"><bold>Parameter</bold></th><th align="center"><bold>All patients (n = 42)</bold></th><th align="center"><bold>Intermittent dosing (n = 18)</bold></th><th align="center"><bold>Continuous infusion (n = 24)</bold></th><th align="center"><bold><italic>P</italic></bold><sup><bold>*</bold></sup></th></tr></thead><tbody valign="top"><tr><td align="left" valign="bottom"><bold>Vancomycin dose (mg/kg)</bold><hr></hr></td><td align="center" valign="bottom">27 [18 - 32]<hr></hr></td><td align="center" valign="bottom">27 [22 - 30]<hr></hr></td><td align="center" valign="bottom">27 [17 - 33]<hr></hr></td><td align="center" valign="bottom">0.611<hr></hr></td></tr><tr><td align="left" valign="bottom"><bold>Elimination rate constant (h</bold><sup><bold>-1</bold></sup><bold>)**</bold><hr></hr></td><td align="center" valign="bottom">0.09 [0.03 - 0.13]<hr></hr></td><td align="center" valign="bottom">0.09 [0.03 - 0.13]<hr></hr></td><td align="center" valign="bottom">-<hr></hr></td><td align="center" valign="bottom">-<hr></hr></td></tr><tr><td align="left" valign="bottom"><bold>Clearance (L/h)</bold><hr></hr></td><td align="center" valign="bottom">3.6 [1.9 - 5.9]<hr></hr></td><td align="center" valign="bottom">5.1 [2.4 - 7.1]<hr></hr></td><td align="center" valign="bottom">2.7 [1.7 - 4.1]<hr></hr></td><td align="center" valign="bottom">0.038<hr></hr></td></tr><tr><td align="left" valign="bottom"><bold>Half-life (h)</bold><sup><bold>**</bold></sup><hr></hr></td><td align="center" valign="bottom">8.2 [5.4 - 24.1]<hr></hr></td><td align="center" valign="bottom">8.2 [5.4 - 24.1]<hr></hr></td><td align="center" valign="bottom">-<hr></hr></td><td align="center" valign="bottom">-<hr></hr></td></tr><tr><td align="left" valign="bottom"><bold>C</bold><sub><bold>min </bold></sub><bold>(mg/L)</bold><hr></hr></td><td align="center" valign="bottom">17 [8 - 23]<hr></hr></td><td align="center" valign="bottom">10 [7- 17]<hr></hr></td><td align="center" valign="bottom">21 [14 - 26]<hr></hr></td><td align="center" valign="bottom">0.029<hr></hr></td></tr><tr><td align="left" valign="bottom"><bold>C</bold><sub><bold>min </bold></sub><bold>≥15 mg/L, n (percentage)</bold><hr></hr></td><td align="center" valign="bottom">24 (57.1)<hr></hr></td><td align="center" valign="bottom">7 (38.9)<hr></hr></td><td align="center" valign="bottom">17 (70.8)<hr></hr></td><td align="center" valign="bottom">0.038<hr></hr></td></tr><tr><td align="left" valign="bottom"><bold>AUC</bold><sub><bold>0–24</bold></sub><bold>/MIC</bold><hr></hr></td><td align="center" valign="bottom">655 [368 - 911]<hr></hr></td><td align="center" valign="bottom">409 [246 - 712]<hr></hr></td><td align="center" valign="bottom">830 [529 - 952]<hr></hr></td><td align="center" valign="bottom">0.029<hr></hr></td></tr><tr><td align="left" valign="bottom"><bold>AUC</bold><sub><bold>0–24</bold></sub><bold>/MIC > 400, n (percentage)</bold><hr></hr></td><td align="center" valign="bottom">30 (71.4)<hr></hr></td><td align="center" valign="bottom">9 (50.0)<hr></hr></td><td align="center" valign="bottom">21 (87.5)<hr></hr></td><td align="center" valign="bottom">0.008<hr></hr></td></tr><tr><td align="left" valign="bottom"><bold>Length of vancomycin therapy on sampling date</bold><hr></hr></td><td align="center" valign="bottom"> <hr></hr></td><td align="center" valign="bottom"> <hr></hr></td><td align="center" valign="bottom"> <hr></hr></td><td align="center" valign="bottom"> <hr></hr></td></tr><tr><td align="left" valign="bottom"> <bold>Days, n</bold><hr></hr></td><td align="center" valign="bottom">4 [1 - 7]<hr></hr></td><td align="center" valign="bottom">2 [1 - 6]<hr></hr></td><td align="center" valign="bottom">4 [1 - 7]<hr></hr></td><td align="center" valign="bottom">0.314<hr></hr></td></tr><tr><td align="left" valign="bottom"> <bold>>2 days, n (percentage)</bold><hr></hr></td><td align="center" valign="bottom">23/41 (56.1)<hr></hr></td><td align="center" valign="bottom">8/18 (44.4)<hr></hr></td><td align="center" valign="bottom">15/23 (65.2)<hr></hr></td><td align="center" valign="bottom">0.183<hr></hr></td></tr><tr><td align="left"> <bold>>3 days, n (percentage)</bold></td><td align="center">22/41 (53.7)</td><td align="center">8/18 (44.4)</td><td align="center">14/23 (60.9)</td><td align="center">0.295</td></tr></tbody></table><table-wrap-foot><p>Data are described as median [1<sup>st</sup> - 3<sup>rd</sup> quartile] or n (%). For pharmacodynamics calculations, an MIC of 1 mg/L was assumed. <sup>*</sup>Indicates difference between intermittent dosing and continuous infusion of vancomycin; <sup>**</sup>could only be determined in patients receiving intermittent dosing. C<sub>min</sub>, minimum concentration of drug observed during the dosing period; AUC<sub>0–24</sub>/MIC, ratio of the area under the concentration-time curve over a 24-hour period divided by the minimum inhibitory concentration of the suspected bacteria.</p></table-wrap-foot></table-wrap><fig id="F1" position="float"><label>Figure 1</label><caption><p><bold>Boxplots of vancomycin dosages administered stratified for renal replacement therapy and various glomerular filtration rates. </bold><sup>*</sup>Data on glomerular filtration were only available in 30 patients. No difference between groups could be demonstrated (<italic>P</italic> = 0.359).</p></caption><graphic xlink:href="cc13874-1"></graphic></fig><p>Target trough concentrations (≥15 mg/L) were achieved in 57% of patients (Table <xref ref-type="table" rid="T2">2</xref>). Trough concentrations did not differ between patients with either RRT or various degrees of glomerular filtration (Figure <xref ref-type="fig" rid="F2">2</xref>) (<italic>P</italic> = 0.233), but were more frequently achieved with continuous infusion therapy (Table <xref ref-type="table" rid="T2">2</xref>). Figure <xref ref-type="fig" rid="F3">3</xref> illustrates trough concentrations according to weight-adjusted daily doses administered and stratified for continuous or intermittent dosing.</p><fig id="F2" position="float"><label>Figure 2</label><caption><p><bold>Boxplot of vancomycin trough concentrations stratified for renal replacement therapy and various glomerular filtration rates. </bold><sup>*</sup>Data on glomerular filtration were only available in 30 patients. Red line indicates vancomycin trough concentration target (15 mg/L). No difference between groups could be demonstrated (<italic>P</italic> = 0.233).</p></caption><graphic xlink:href="cc13874-2"></graphic></fig><fig id="F3" position="float"><label>Figure 3</label><caption><p><bold>Vancomycin trough concentration according to daily dose administered. </bold><sup>*</sup>Red line indicates target trough concentration of 15 mg/L; circles represent patients with continuous infusion; triangles represent patients with intermittent dosing. Spearman rank correlation for (i) all patients: R = 0.540 (<italic>P</italic> <0.001), (ii) patients with continuous infusion: R = 0.587 (<italic>P</italic> = 0.062), and patients with intermittent dosing: R = 0.127 (<italic>P</italic> = 0.615).</p></caption><graphic xlink:href="cc13874-3"></graphic></fig><p>The target AUC<sub>0–24</sub>/MIC (>400) was reached in 71% of the study subjects if an MIC = 1 mg/L was assumed. If MIC values of 0.5 or 2 mg/L were used, then the AUC<sub>0–24</sub>/MIC (>400) target would have been reached in 88% and 38% of patients, respectively. AUC<sub>0–24</sub>/MIC ratios were not statistically significantly different between patients with RRT or distinct degrees of glomerular filtration (Figure <xref ref-type="fig" rid="F4">4</xref>) (<italic>P</italic> = 0.224). The target AUC<sub>0–24</sub>/MIC ratio was more frequently achieved with continuous infusion therapy (Figure <xref ref-type="fig" rid="F5">5</xref>) (<italic>P</italic> = 0.008).</p><fig id="F4" position="float"><label>Figure 4</label><caption><p><bold>Boxplot of vancomycin AUC</bold><sub><bold>0–24</bold></sub><bold>/MIC ratios stratified for renal replacement therapy and various glomerular filtration rates. </bold><sup>*</sup>Data on glomerular filtration were only available in 30 patients. Red line indicates the AUC<sub>0–24</sub>/MIC target ratio (400). No difference between the groups could be demonstrated (<italic>P</italic> = 0.224). AUC<sub>0–24</sub>/MIC, ratio of the area under the concentration-time curve over a 24-hour period divided by the minimum inhibitory concentration of the suspected bacteria.</p></caption><graphic xlink:href="cc13874-4"></graphic></fig><fig id="F5" position="float"><label>Figure 5</label><caption><p><bold>AUC</bold><sub><bold>0</bold>–<bold>24</bold></sub>/<bold>MIC ratios of vancomycin for intermittent dosing versus continuous infusion. </bold><sup>*</sup>Boxes indicate lower quartile (bottom of box), median (band near the middle of the box), and upper quartile (top of the box); whiskers indicate the lowest value still within 1.5 of the interquartile range from the lower quartile, and the highest value still within 1.5 of the interquartile range from the upper quartile; circles indicate outliers. The red line indicates the minimum the target threshold for optimizing outcomes (AUC<sub>0–24</sub>/MIC >400). Difference between the groups: <italic>P</italic> = 0.029. AUC<sub>0–24</sub>/MIC, ratio of the area under the concentration-time curve over a 24-hour period divided by the minimum inhibitory concentration of the suspected bacteria.</p></caption><graphic xlink:href="cc13874-5"></graphic></fig><p>Table <xref ref-type="table" rid="T3">3</xref> describes univariate relationships between covariates and PD target values as assessed by logistic regression analyses. Multivariable logistic regression analysis with adjustment by the propensity score could not confirm continuous infusion as an independent predictor of an AUC<sub>0–24</sub>/MIC >400 (OR 1.65, 95% CI 0.2 to 12.0) or a C<sub>min</sub> ≥15 mg/L (OR 1.8, 95% CI 0.4 to 8.5). Hosmer and Lemeshow tests for both models were respectively <italic>P</italic> = 0.660 and <italic>P</italic> = 0.506.</p><table-wrap position="float" id="T3"><label>Table 3</label><caption><p><bold>Unadjusted relationships with AUC</bold><sub><bold>0–24</bold></sub><bold>/MIC ratio >400 and target trough concentrations (>15 mg/L)</bold></p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"></col><col align="center"></col><col align="center"></col><col align="center"></col><col align="center"></col></colgroup><thead valign="top"><tr><th align="left" valign="bottom"><bold>Variable</bold><hr></hr></th><th colspan="2" align="center" valign="bottom"><bold>Unadjusted relationships with AUC</bold><sub><bold>0–24</bold></sub><bold>/MIC ratio >400</bold><hr></hr></th><th colspan="2" align="center" valign="bottom"><bold>Unadjusted relationships with C</bold><sub><bold>min </bold></sub><bold>>15 mg/L</bold><hr></hr></th></tr><tr><th align="left"> </th><th align="center"><bold>OR (95% CI)</bold></th><th align="center"><bold><italic>P</italic></bold></th><th align="center"><bold>OR (95% CI)</bold></th><th align="center"><bold><italic>P</italic></bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="bottom"><bold>Age (/year increase)</bold><hr></hr></td><td align="center" valign="bottom">0.99 (0.95 - 1.03)<hr></hr></td><td align="center" valign="bottom">0.547<hr></hr></td><td align="center" valign="bottom">0.99 (0.96 - 1.03)<hr></hr></td><td align="center" valign="bottom">0.723<hr></hr></td></tr><tr><td align="left" valign="bottom"><bold>Male sex</bold><hr></hr></td><td align="center" valign="bottom">0.59 (0.13 - 2.69)<hr></hr></td><td align="center" valign="bottom">0.499<hr></hr></td><td align="center" valign="bottom">1.20 (0.33 - 4.32)<hr></hr></td><td align="center" valign="bottom">0.780<hr></hr></td></tr><tr><td align="left" valign="bottom"><bold>SOFA score (/point increase)</bold><hr></hr></td><td align="center" valign="bottom">1.10 (0.91 - 1.32)<hr></hr></td><td align="center" valign="bottom">0.318<hr></hr></td><td align="center" valign="bottom">1.05 (0.91 - 1.21)<hr></hr></td><td align="center" valign="bottom">0.519<hr></hr></td></tr><tr><td align="left" valign="bottom"><bold>Renal replacement therapy</bold><hr></hr></td><td align="center" valign="bottom">3.64 (0.40 - 33.12)<hr></hr></td><td align="center" valign="bottom">0.252<hr></hr></td><td align="center" valign="bottom">3.29 (0.59 - 18.3)<hr></hr></td><td align="center" valign="bottom">0.173<hr></hr></td></tr><tr><td align="left" valign="bottom"><bold>Fluid balance of the latest 24 hours</bold><hr></hr></td><td align="center" valign="bottom"> <hr></hr></td><td align="center" valign="bottom"> <hr></hr></td><td align="center" valign="bottom"> <hr></hr></td><td align="center" valign="bottom"> <hr></hr></td></tr><tr><td align="left" valign="bottom"> <bold>Negative fluid balance</bold><hr></hr></td><td align="center" valign="bottom">2.20 (0.49 - 9.88)<hr></hr></td><td align="center" valign="bottom">0.305<hr></hr></td><td align="center" valign="bottom">1.12 (0.32 - 3.91)<hr></hr></td><td align="center" valign="bottom">0.856<hr></hr></td></tr><tr><td align="left" valign="bottom"> <bold>Negative fluid balance >1000 mL</bold><hr></hr></td><td align="center" valign="bottom">2.40 (0.26 - 22.55)<hr></hr></td><td align="center" valign="bottom">0.444<hr></hr></td><td align="center" valign="bottom">1.00 (0.19 - 5.15)<hr></hr></td><td align="center" valign="bottom">0.999<hr></hr></td></tr><tr><td align="left" valign="bottom"> <bold>Positive fluid balance</bold><hr></hr></td><td align="center" valign="bottom">0.46 (0.10 - 2.05)<hr></hr></td><td align="center" valign="bottom">0.305<hr></hr></td><td align="center" valign="bottom">0.89 (0.26 - 3.10)<hr></hr></td><td align="center" valign="bottom">0.856<hr></hr></td></tr><tr><td align="left" valign="bottom"> <bold>Positive fluid balance >1000 mL</bold><hr></hr></td><td align="center" valign="bottom">0.46 (0.11 - 1.85)<hr></hr></td><td align="center" valign="bottom">0.273<hr></hr></td><td align="center" valign="bottom">0.75 (0.22 - 2.60)<hr></hr></td><td align="center" valign="bottom">0.650<hr></hr></td></tr><tr><td align="left" valign="bottom"> <bold>Positive fluid balance >2000 mL</bold><hr></hr></td><td align="center" valign="bottom">0.23 (0.05 - 1.06)<hr></hr></td><td align="center" valign="bottom">0.059<hr></hr></td><td align="center" valign="bottom">0.68 (0.16 - 2.85)<hr></hr></td><td align="center" valign="bottom">0.602<hr></hr></td></tr><tr><td align="left" valign="bottom"><bold>Serum creatinine, mg/dL (/mg increase)</bold><hr></hr></td><td align="center" valign="bottom">1.02 (0.71 - 1.48)<hr></hr></td><td align="center" valign="bottom">0.914<hr></hr></td><td align="center" valign="bottom">2.71 (0.78 - 9.37)<hr></hr></td><td align="center" valign="bottom">0.116<hr></hr></td></tr><tr><td align="left" valign="bottom"><bold>Creatinine clearance, mL/min. (/mL increase)</bold><hr></hr></td><td align="center" valign="bottom">1.02 (0.99 - 1.04)<hr></hr></td><td align="center" valign="bottom">0.194<hr></hr></td><td align="center" valign="bottom">1.00 (0.98 - 1.01<hr></hr></td><td align="center" valign="bottom">0.457<hr></hr></td></tr><tr><td align="left" valign="bottom"><bold>Infection source pneumonia or intra-abdominal infection</bold><hr></hr></td><td align="center" valign="bottom">2.84 (0.52 - 15.47)<hr></hr></td><td align="center" valign="bottom">0.227<hr></hr></td><td align="center" valign="bottom">4.2 (0.97 - 18.53)<hr></hr></td><td align="center" valign="bottom">0.056<hr></hr></td></tr><tr><td align="left" valign="bottom"><bold>Vancomycin dose, mg/kg (/mg increase)</bold><hr></hr></td><td align="center" valign="bottom">1.03 (0.97 - 1.10)<hr></hr></td><td align="center" valign="bottom">0.319<hr></hr></td><td align="center" valign="bottom">1.06 (0.99 - 1.14)<hr></hr></td><td align="center" valign="bottom">0.071<hr></hr></td></tr><tr><td align="left" valign="bottom"><bold>Continuous infusion of vancomycin</bold><hr></hr></td><td align="center" valign="bottom">11.00 (1.98 - 61.26)<hr></hr></td><td align="center" valign="bottom">0.006<hr></hr></td><td align="center" valign="bottom">3.82 (1.05 - 13.91)<hr></hr></td><td align="center" valign="bottom">0.042<hr></hr></td></tr><tr><td align="left" valign="bottom"><bold>Length of vancomycin therapy at sampling date</bold><hr></hr></td><td align="center" valign="bottom"> <hr></hr></td><td align="center" valign="bottom"> <hr></hr></td><td align="center" valign="bottom"> <hr></hr></td><td align="center" valign="bottom"> <hr></hr></td></tr><tr><td align="left" valign="bottom"> <bold>Days (/day increase)</bold><hr></hr></td><td align="center" valign="bottom">1.35 (1.02 - 1.79)<hr></hr></td><td align="center" valign="bottom">0.034<hr></hr></td><td align="center" valign="bottom">0.94 (0.82 - 1.08)<hr></hr></td><td align="center" valign="bottom">0.370<hr></hr></td></tr><tr><td align="left" valign="bottom"> <bold>>2 days</bold><hr></hr></td><td align="center" valign="bottom">10.50 (1.88 - 58.62)<hr></hr></td><td align="center" valign="bottom">0.007<hr></hr></td><td align="center" valign="bottom">1.56 (0.45 - 5.41)<hr></hr></td><td align="center" valign="bottom">0.487<hr></hr></td></tr><tr><td align="left"> <bold>>3 days</bold></td><td align="center">9.00 (1.63 - 49.76)</td><td align="center">0.012</td><td align="center">1.30 (0.38 - 4.49)</td><td align="center">0.687</td></tr></tbody></table><table-wrap-foot><p>AUC<sub>0–24</sub>/MIC, ratio of the area under the concentration-time curve over a 24-hour period divided by the minimum inhibitory concentration of the suspected bacteria; C<sub>min</sub>, minimum concentration of drug observed during the dosing period; OR, odds ratio; CI, confidence interval; SOFA, sequential organ failure assessment.</p></table-wrap-foot></table-wrap></sec><sec sec-type="discussion"><title>Discussion</title><p>This is the first large-scale multicentre point-prevalence study investigating pharmacokinetics and PK/PD target attainment of vancomycin in critically ill patients. The present study revealed that a substantial proportion of patients did not achieve the target vancomycin exposures. Forty-five percent of patients did not reach the minimum C<sub>min</sub> threshold (≥15 mg/L) while 26% did not reach an AUC<sub>0–24</sub>/MIC ratio >400. The latter index is generally considered as the most important factor for enhancing effectiveness of vancomycin. Several investigators have demonstrated that an AUC<sub>0–24</sub>/MIC ratio above 400 is required to optimise clinical outcomes [<xref ref-type="bibr" rid="B4">4</xref>-<xref ref-type="bibr" rid="B6">6</xref>]. It has been proposed that even higher index of exposure might be necessary in critically ill patients. In a cohort of patients with MRSA-associated septic shock, Zelenitsky <italic>et al.</italic> identified a threshold of AUC<sub>0–24</sub>/MIC >578 to be associated with higher likelihood of survival, while an AUC<sub>0–24</sub>/MIC <451 was associated with increased odds of death [<xref ref-type="bibr" rid="B15">15</xref>]. A threshold AUC<sub>0–24</sub>/MIC >578 is substantially higher than the standard cut-off ratio >400. In the present study only 24 patients (57%) reached an AUC<sub>0–24</sub>/MIC >578.</p><p>Another important observation from this study is the high variability in pharmacokinetics parameters. Wide ranges in C<sub>min</sub>, AUC<sub>0–24</sub>, and half-life were observed, and illustrate the challenge of vancomycin dosing in critically ill patients in comparison with mild-to-moderately sick patients in which pharmacokinetics is much more stable and, as such, predictable [<xref ref-type="bibr" rid="B19">19</xref>]. High interpatient variability in pharmacokinetics of antibiotics in critically ill patients has been reported previously [<xref ref-type="bibr" rid="B20">20</xref>-<xref ref-type="bibr" rid="B22">22</xref>]. Standard doses of the concentration-dependent agents amikacin and ciprofloxacin proved inadequate to achieve target peak concentrations in ICU patients [<xref ref-type="bibr" rid="B20">20</xref>,<xref ref-type="bibr" rid="B21">21</xref>]. Also standard dosing approaches for beta-lactam antibiotics appeared to be insufficient to achieve target concentrations in the early phase of sepsis [<xref ref-type="bibr" rid="B22">22</xref>]. Despite the generally accepted use of therapeutic drug monitoring (TDM) in vancomycin therapy and the administration of a wide range of doses in the present study, dosing was frequently suboptimal. Besides TDM data, dosing should be based on patient’s weight, and renal function. The average daily vancomycin doses administered for patients receiving RRT and patients with a GFR of 51 to 100 mL/min. or >100 mL/min., ranged from 20 to 30 mg/kg (Figure <xref ref-type="fig" rid="F1">1</xref>), and are therefore in accordance with recommendations. Notwithstanding this, more than half of the patients with GFR 51 to 100 or GFR >100 mL/min. did not achieve the target trough concentration of ≥15 mg/L (Figure <xref ref-type="fig" rid="F2">2</xref>). Particularly in the patient group with GFR 51 to 100 mL/min. adequate dosing seems to be problematic with a median C<sub>min</sub> of 9 mg/L and high variability despite reasonable dosages administered. In patients with more impaired renal function (GFR 0 to 30 mL/min.) doses were restricted (median 10 mg/kg), also leading to inadequate trough concentrations in half of the patients. Patients receiving RRT most frequently achieved satisfying trough concentrations.</p><p>In the present study, continuous infusion of vancomycin appeared more successful for reaching target PD parameters than intermittent dosing (Tables <xref ref-type="table" rid="T2">2</xref> and <xref ref-type="table" rid="T3">3</xref>). However, logistic regression failed to confirm this relationship. Continuous infusion of vancomycin in critically ill patients has been advocated before [<xref ref-type="bibr" rid="B23">23</xref>,<xref ref-type="bibr" rid="B24">24</xref>]. Although not recommended by the guidelines for the treatment of <italic>S. aureus</italic> infections or vancomycin therapy [<xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B3">3</xref>], the agent appears to be increasingly administered by continuous infusion. The present data cannot underscore the value of continuous infusion therapy for more consistently achieving PK/PD targets in this group of patients. Yet, previous reports stressed the potential value of continuously infused vancomycin stating that it may result in faster achievement of target concentrations [<xref ref-type="bibr" rid="B25">25</xref>], as well as more stable drug concentrations [<xref ref-type="bibr" rid="B26">26</xref>,<xref ref-type="bibr" rid="B27">27</xref>]. Although it seems reasonable to assume more favourable outcomes when PK/PD is optimised, clinical outcome data favouring continuous infusion are far from conclusive. In a cohort of patients with ventilator-associated pneumonia, Rello <italic>et al.</italic> found lower mortality rates in patients receiving vancomycin by continuous infusion (25% vs<italic>.</italic> 55%; <italic>P</italic> = 0.03) [<xref ref-type="bibr" rid="B28">28</xref>]. Although this finding was confirmed by logistic regression analysis, it should be interpreted cautiously as the study was primarily not designed for this purpose [<xref ref-type="bibr" rid="B24">24</xref>].</p><p>This point-prevalence study shows that vancomycin dosing practice results in too many patients being underdosed even with the availability of TDM. In order to overcome the risk of inadequate concentrations, new approaches should be considered such as the use of weight-based loading doses [<xref ref-type="bibr" rid="B13">13</xref>] as well as administration by continuous infusion. In one study by De Waele <italic>et al.</italic>, administering a loading dose of 1000 mg (<65 kg) or 1500 mg (>65 kg) followed by a continuous infusion of 2000 mg/24 h, the authors found that 78% and 88% of critically ill patients reached a serum concentration ≥15 mg/L on day two and three respectively [<xref ref-type="bibr" rid="B29">29</xref>]. In a dosing simulation analysis, Roberts <italic>et al.</italic> demonstrated that at least 35 mg/kg/24 h administered by continuous infusion is needed to maintain a concentrations ≥20 mg/L in some patients [<xref ref-type="bibr" rid="B13">13</xref>]. Alternatively, some authors have proposed the use of a vancomycin dosing nomogram for ICU patients. One recent nomogram that takes into account body weight for loading and maintenance dosing, and the Modification of Diet in Renal Disease equation for dosing frequency [<xref ref-type="bibr" rid="B30">30</xref>]. Although the nomogram resulted in a significant increase in patients achieving the target trough concentration, still 28% of patients had sub-therapeutic vancomycin exposures. Given the high variability in vancomycin concentrations, TDM should be considered essential, but as shown from this data, does not guarantee achievement of target concentrations.</p><p>This study has some limitations. First, we could not evaluate clinical outcome data as only nine patients had documented Gram-positive infections, the remaining patients were administered empiric therapy. However, this data does provide good insight into the PK/PD exposures of vancomycin that occur with contemporary dosing approaches. Second, PD calculations used assumed MIC values. For detailed analyses an assumed MIC = 1 mg/L was used because in Europe only 8% of <italic>S. aureus</italic> MICs for vancomycin are >1 mg/L [<xref ref-type="bibr" rid="B31">31</xref>]. Third, no data about potential loading doses were available.</p></sec><sec sec-type="conclusions"><title>Conclusions</title><p>In conclusion, this study demonstrated large variability in vancomycin pharmacokinetics and PK/PD target attainment in critically ill patients. Continuous infusion was associated with higher likelihood to achieving clinically relevant trough concentrations (of ≥15 mg/L) pharmacodynamic exposure (AUC<sub>0–24</sub>/MIC ratio >400) in univariate analyses but not in multivariate analyses. These data support a re-evaluation of vancomycin dosing recommendations in critically ill patients with new approaches to more rapidly and consistently achieve clinically relevant PK/PD targets.</p></sec><sec><title>Key messages</title><p>• We analysed vancomycin concentrations from 42 patients across 26 ICUs in eight countries. The indication for vancomycin was empiric (not directed) in 74% of cases.</p><p>• A total of 57% of patients were administered vancomycin by continuous infusion, although there was no difference in dose with patients administered intermittent dosing (27 mg/kg/day).</p><p>• Only 57% of patients achieved the target concentration (≥15 mg/L) and only 71% achieved a target AUC<sub>0–24</sub>/MIC of 400 (assuming a MIC of 1 mg/L).</p><p>• Although univariate analysis showed therapeutic targets were more consistently achieved with continuous infusion compared with intermittent dosing (<italic>P</italic> = 0.008), in multivariable logistic regression with adjustment by propensity score, this statistical significance was not maintained.</p></sec><sec><title>Abbreviations</title><p>AKI: acute kidney injury; APACHE II: acute physiology and chronic health evaluation II score; ARC: augmented renal clearance; AUC<sub>0–12</sub>: area under the concentration time curve from 0 to 12 hours; AUC<sub>0–24</sub>/MIC: ratio of the area under the concentration-time curve over a 24-hour period divided by the minimum inhibitory concentration of the suspected bacteria; CI: confidence interval; CL: clearance; C<sub>max</sub>: maximum concentration of drug observed during the dosing period; C<sub>min</sub>: minimum concentration of drug observed during the dosing period; CRF: case report form; DALI: Defining Antibiotic Levels in Intensive Care; ESI: electrospray ionization; GFR: glomerular filtration rate; HFBA: heptafluorobutyric acid; HPLC: high-performance liquid chromatography; ICU: intensive care unit; kel: apparent terminal elimination rate constant; MIC: minimum inhibitory concentration of the suspected bacteria; MRM: multiple reaction monitoring; MRSA: methicillin-resistant <italic>Staphylococcus aureus</italic>; OR: odds ratio; PK: pharmacokinetics; PK/PD: pharmacokinetic/pharmacodynamic; RRT: renal replacement therapy; SD: standard deviation; SOFA: sequential organ failure assessment score; T<sub>1/2</sub>: half-life; TDM: therapeutic drug monitoring.</p></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec><title>Authors’ contributions</title><p>SB contributed to the analysis, interpretation, manuscript writing and final approval of the manuscript; DK contributed to the conception and design, data collection, analysis, interpretation, manuscript writing and final approval of the manuscript; MA contributed to the data collection, analysis, interpretation, manuscript writing and final approval of the manuscript; MB contributed to the data collection, analysis, interpretation, manuscript writing and final approval of the manuscript; JJD contributed to the conception and design, data collection, interpretation, manuscript writing and final approval of the manuscript; GD contributed to the conception and design, data collection, interpretation, manuscript writing and final approval of the manuscript; KMK contributed to the data collection, interpretation, manuscript writing and final approval of the manuscript; CM contributed to the conception and design, data collection, interpretation, manuscript writing and final approval of the manuscript; PM contributed to the conception and design, data collection, interpretation, manuscript writing and final approval of the manuscript; JR contributed to the conception and design, data collection, interpretation, manuscript writing and final approval of the manuscript; AR contributed to the conception and design, data collection, interpretation, manuscript writing and final approval of the manuscript; TS contributed to the conception and design, data collation, manuscript writing and final approval of the manuscript; SW contributed to the conception and design, analysis, interpretation, manuscript writing and final approval of the manuscript; JL contributed to the conception and design, interpretation, manuscript writing and final approval of the manuscript; JAR contributed to the conception and design, analysis, interpretation, manuscript writing and final approval of the manuscript. All authors read and approved the final manuscript.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="S1"><caption><title>Additional file 1</title><p>A list of the DALI study authors.</p></caption><media xlink:href="cc13874-S1.docx"><caption><p>Click here for file</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="S2"><caption><title>Additional file 2</title><p>A list of the contributing sites and their ethical approval bodies.</p></caption><media xlink:href="cc13874-S2.docx"><caption><p>Click here for file</p></caption></media></supplementary-material></sec></body><back><sec><title>Acknowledgements</title><p>This study was partly funded by the European Society of Intensive Care Medicine and the Royal Brisbane and Women’s Hospital Foundation, Australia. SB holds a research mandate from the special research fund at Ghent University. Dr Roberts is funded by a Career Development Fellowship from the National Health and Medical Research Council of Australia (APP1048652). There are no other relevant sources of funding for any of the authors. None of the above sources of funding had any role in the design, in the collection, analysis, and interpretation of data; in the writing of the manuscript; or in the decision to submit the manuscript for publication. We also acknowledge the DALI study authors (listed below) for their assistance with this study.</p></sec><ref-list><ref id="B1"><mixed-citation publication-type="journal"><name><surname>Boucher</surname><given-names>H</given-names></name><name><surname>Miller</surname><given-names>LG</given-names></name><name><surname>Razonable</surname><given-names>RR</given-names></name><article-title>Serious infections caused by methicillin-resistant Staphylococcus aureus</article-title><source>Clin Infect Dis</source><year>2010</year><volume>51</volume><fpage>S183</fpage><lpage>S197</lpage><pub-id pub-id-type="doi">10.1086/653519</pub-id><pub-id pub-id-type="pmid">20731576</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Bayer</surname><given-names>A</given-names></name><name><surname>Cosgrove</surname><given-names>SE</given-names></name><name><surname>Daum</surname><given-names>RS</given-names></name><name><surname>Fridkin</surname><given-names>SK</given-names></name><name><surname>Gorwitz</surname><given-names>RJ</given-names></name><name><surname>Kaplan</surname><given-names>SL</given-names></name><name><surname>Karchmer</surname><given-names>AW</given-names></name><name><surname>Levine</surname><given-names>DP</given-names></name><name><surname>Murray</surname><given-names>BE</given-names></name><name><surname>Rybak</surname><given-names>MJ</given-names></name><name><surname>Talan</surname><given-names>DA</given-names></name><name><surname>Chambers</surname><given-names>HF</given-names></name><article-title>Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary</article-title><source>Clin Infect Dis</source><year>2011</year><volume>52</volume><fpage>285</fpage><lpage>292</lpage><pub-id pub-id-type="doi">10.1093/cid/cir034</pub-id><pub-id pub-id-type="pmid">21217178</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><name><surname>Rybak</surname><given-names>MJ</given-names></name><name><surname>Lomaestro</surname><given-names>BM</given-names></name><name><surname>Rotschafer</surname><given-names>JC</given-names></name><name><surname>Moellering</surname><given-names>RC</given-names></name><name><surname>Craig</surname><given-names>WA</given-names></name><name><surname>Billeter</surname><given-names>M</given-names></name><name><surname>Dalovisio</surname><given-names>JR</given-names></name><name><surname>Levine</surname><given-names>DP</given-names></name><article-title>Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists</article-title><source>Clin Infect Dis</source><year>2009</year><volume>49</volume><fpage>325</fpage><lpage>327</lpage><pub-id pub-id-type="doi">10.1086/600877</pub-id><pub-id pub-id-type="pmid">19569969</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><name><surname>Moise-Broder</surname><given-names>PA</given-names></name><name><surname>Forrest</surname><given-names>A</given-names></name><name><surname>Birmingham</surname><given-names>MC</given-names></name><name><surname>Schentag</surname><given-names>JJ</given-names></name><article-title>Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections</article-title><source>Clin Pharmacokinet</source><year>2004</year><volume>43</volume><fpage>925</fpage><lpage>942</lpage><pub-id pub-id-type="doi">10.2165/00003088-200443130-00005</pub-id><pub-id pub-id-type="pmid">15509186</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><name><surname>Holmes</surname><given-names>NE</given-names></name><name><surname>Turnidge</surname><given-names>JD</given-names></name><name><surname>Munckhof</surname><given-names>WJ</given-names></name><name><surname>Robinson</surname><given-names>JO</given-names></name><name><surname>Korman</surname><given-names>TM</given-names></name><name><surname>O'Sullivan</surname><given-names>MV</given-names></name><name><surname>Anderson</surname><given-names>TL</given-names></name><name><surname>Roberts</surname><given-names>SA</given-names></name><name><surname>Warren</surname><given-names>SJ</given-names></name><name><surname>Gao</surname><given-names>W</given-names></name><name><surname>Howden</surname><given-names>BP</given-names></name><name><surname>Johnson</surname><given-names>PD</given-names></name><article-title>Vancomycin AUC/MIC ratio and 30-day mortality in patients with Staphylococcus aureus bacteremia</article-title><source>Antimicrob Agents Chemother</source><year>2013</year><volume>57</volume><fpage>1654</fpage><lpage>1663</lpage><pub-id pub-id-type="doi">10.1128/AAC.01485-12</pub-id><pub-id pub-id-type="pmid">23335735</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><name><surname>Kullar</surname><given-names>R</given-names></name><name><surname>Davis</surname><given-names>SL</given-names></name><name><surname>Levine</surname><given-names>DP</given-names></name><name><surname>Rybak</surname><given-names>MJ</given-names></name><article-title>Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets</article-title><source>Clin Infect Dis</source><year>2011</year><volume>52</volume><fpage>975</fpage><lpage>981</lpage><pub-id pub-id-type="doi">10.1093/cid/cir124</pub-id><pub-id pub-id-type="pmid">21460309</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><name><surname>Roberts</surname><given-names>JA</given-names></name><name><surname>Lipman</surname><given-names>J</given-names></name><article-title>Pharmacokinetic issues for antibiotics in the critically ill patient</article-title><source>Crit Care Med</source><year>2009</year><volume>37</volume><fpage>840</fpage><lpage>851</lpage><pub-id pub-id-type="doi">10.1097/CCM.0b013e3181961bff</pub-id><pub-id pub-id-type="pmid">19237886</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><name><surname>Udy</surname><given-names>AA</given-names></name><name><surname>Roberts</surname><given-names>JA</given-names></name><name><surname>Lipman</surname><given-names>J</given-names></name><article-title>Implications of augmented renal clearance in critically ill patients</article-title><source>Nat Rev Nephrol</source><year>2011</year><volume>7</volume><fpage>539</fpage><lpage>543</lpage><pub-id pub-id-type="doi">10.1038/nrneurol.2011.141</pub-id><pub-id pub-id-type="pmid">21769107</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><name><surname>Roberts</surname><given-names>JA</given-names></name><name><surname>Paul</surname><given-names>SK</given-names></name><name><surname>Akova</surname><given-names>M</given-names></name><name><surname>Bassetti</surname><given-names>M</given-names></name><name><surname>De Waele</surname><given-names>JJ</given-names></name><name><surname>Dimopoulos</surname><given-names>G</given-names></name><name><surname>Kaukonen</surname><given-names>K-M</given-names></name><name><surname>Koulenti</surname><given-names>D</given-names></name><name><surname>Martin</surname><given-names>C</given-names></name><name><surname>Montravers</surname><given-names>P</given-names></name><name><surname>Rello</surname><given-names>J</given-names></name><name><surname>Rhodes</surname><given-names>A</given-names></name><name><surname>Starr</surname><given-names>T</given-names></name><name><surname>Wallis</surname><given-names>SC</given-names></name><name><surname>Lipman</surname><given-names>J</given-names></name><collab>DALI Study Authors</collab><article-title>DALI: Defining Antibiotic Levels in Intensive care unit patients: are current beta-lactam antibiotic doses sufficient for critically ill patients?</article-title><source>Clin Infect Dis</source><year>2014</year><volume>58</volume><fpage>1072</fpage><lpage>1833</lpage><pub-id pub-id-type="doi">10.1093/cid/ciu027</pub-id><pub-id pub-id-type="pmid">24429437</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><name><surname>Roberts</surname><given-names>DM</given-names></name><name><surname>Roberts</surname><given-names>JA</given-names></name><name><surname>Roberts</surname><given-names>MS</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Nair</surname><given-names>P</given-names></name><name><surname>Cole</surname><given-names>L</given-names></name><name><surname>Lipman</surname><given-names>J</given-names></name><name><surname>Bellomo</surname><given-names>R</given-names></name><article-title>Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy: a multicentre pharmacokinetic study</article-title><source>Crit Care Med</source><year>2012</year><volume>40</volume><fpage>1523</fpage><lpage>1528</lpage><pub-id pub-id-type="doi">10.1097/CCM.0b013e318241e553</pub-id><pub-id pub-id-type="pmid">22511133</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><name><surname>Jamal</surname><given-names>JA</given-names></name><name><surname>Economou</surname><given-names>CJ</given-names></name><name><surname>Lipman</surname><given-names>J</given-names></name><name><surname>Roberts</surname><given-names>JA</given-names></name><article-title>Improving antibiotic dosing in special situations in the ICU: burns, renal replacement therapy and extracorporeal membrane oxygenation</article-title><source>Curr Opin Crit Care</source><year>2012</year><volume>18</volume><fpage>460</fpage><lpage>471</lpage><pub-id pub-id-type="doi">10.1097/MCC.0b013e32835685ad</pub-id><pub-id pub-id-type="pmid">22820155</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Udy</surname><given-names>AA</given-names></name><name><surname>Kirkpatrick</surname><given-names>CM</given-names></name><name><surname>Lipman</surname><given-names>J</given-names></name><name><surname>Roberts</surname><given-names>JA</given-names></name><article-title>Improving vancomycin prescription in critical illness through a drug use evaluation process: a weight-based dosing intervention study</article-title><source>Int J Antimicrob Agents</source><year>2012</year><volume>39</volume><fpage>69</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2011.08.017</pub-id><pub-id pub-id-type="pmid">22024354</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><name><surname>Roberts</surname><given-names>JA</given-names></name><name><surname>Taccone</surname><given-names>FS</given-names></name><name><surname>Udy</surname><given-names>AA</given-names></name><name><surname>Vincent</surname><given-names>JL</given-names></name><name><surname>Jacobs</surname><given-names>F</given-names></name><name><surname>Lipman</surname><given-names>J</given-names></name><article-title>Vancomycin dosing in critically ill patients: robust methods for improved continuous-infusion regimens</article-title><source>Antimicrob Agents Chemother</source><year>2011</year><volume>55</volume><fpage>2704</fpage><lpage>2709</lpage><pub-id pub-id-type="doi">10.1128/AAC.01708-10</pub-id><pub-id pub-id-type="pmid">21402850</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><name><surname>Udy</surname><given-names>AA</given-names></name><name><surname>Covajes</surname><given-names>C</given-names></name><name><surname>Taccone</surname><given-names>FS</given-names></name><name><surname>Jacobs</surname><given-names>F</given-names></name><name><surname>Vincent</surname><given-names>JL</given-names></name><name><surname>Lipman</surname><given-names>J</given-names></name><name><surname>Roberts</surname><given-names>JA</given-names></name><article-title>Can population pharmacokinetic modelling guide vancomycin dosing during continuous renal replacement therapy in critically ill patients?</article-title><source>Int J Antimicrob Agents</source><year>2013</year><volume>41</volume><fpage>564</fpage><lpage>568</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2013.01.018</pub-id><pub-id pub-id-type="pmid">23473944</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><name><surname>Zelenitsky</surname><given-names>S</given-names></name><name><surname>Rubinstein</surname><given-names>E</given-names></name><name><surname>Ariano</surname><given-names>R</given-names></name><name><surname>Iacovides</surname><given-names>H</given-names></name><name><surname>Dodek</surname><given-names>P</given-names></name><name><surname>Mirzanejad</surname><given-names>Y</given-names></name><name><surname>Kumar</surname><given-names>A</given-names></name><article-title>Vancomycin pharmacodynamics and survival in patients with methicillin-resistant Staphylococcus aureus-associated septic shock</article-title><source>Int J Antimicrob Agents</source><year>2013</year><volume>41</volume><fpage>255</fpage><lpage>260</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2012.10.015</pub-id><pub-id pub-id-type="pmid">23312606</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><name><surname>Brown</surname><given-names>J</given-names></name><name><surname>Brown</surname><given-names>K</given-names></name><name><surname>Forrest</surname><given-names>A</given-names></name><article-title>Vancomycin AUC24/MIC ratio in patients with complicated bacteremia and infective endocarditis due to methicillin-resistant Staphylococcus aureus and its association with attributable mortality during hospitalization</article-title><source>Antimicrob Agents Chemother</source><year>2012</year><volume>56</volume><fpage>634</fpage><lpage>638</lpage><pub-id pub-id-type="doi">10.1128/AAC.05609-11</pub-id><pub-id pub-id-type="pmid">22123681</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><name><surname>Roberts</surname><given-names>JA</given-names></name><name><surname>De Waele</surname><given-names>JJ</given-names></name><name><surname>Dimopoulos</surname><given-names>G</given-names></name><name><surname>Koulenti</surname><given-names>D</given-names></name><name><surname>Martin</surname><given-names>C</given-names></name><name><surname>Montravers</surname><given-names>P</given-names></name><name><surname>Rello</surname><given-names>J</given-names></name><name><surname>Rhodes</surname><given-names>A</given-names></name><name><surname>Starr</surname><given-names>T</given-names></name><name><surname>Wallis</surname><given-names>SC</given-names></name><name><surname>Lipman</surname><given-names>J</given-names></name><article-title>DALI: Defining Antibiotic Levels in Intensive care unit patients: a multi-centre point of prevalence study to determine whether contemporary antibiotic dosing for critically ill patients is therapeutic</article-title><source>BMC Infect Dis</source><year>2012</year><volume>12</volume><fpage>152</fpage><pub-id pub-id-type="doi">10.1186/1471-2334-12-152</pub-id><pub-id pub-id-type="pmid">22768873</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="book"><collab>Food and Drink Administration</collab><source>Guidance for industry: bioanalytical method validation</source><publisher-name>US Department of Health and Human Services, Center for Drug Evaluation and Research</publisher-name><comment>Available at: [<ext-link ext-link-type="uri" xlink:href="http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070107.pdf">http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070107.pdf</ext-link>]</comment></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><name><surname>Matzke</surname><given-names>GR</given-names></name><name><surname>McGory</surname><given-names>RW</given-names></name><name><surname>Halstenson</surname><given-names>CE</given-names></name><name><surname>Keane</surname><given-names>WF</given-names></name><article-title>Pharmacokinetics of vancomycin in patients with various degrees of renal function</article-title><source>Antimicrob Agents Chemother</source><year>1984</year><volume>25</volume><fpage>433</fpage><lpage>437</lpage><pub-id pub-id-type="doi">10.1128/AAC.25.4.433</pub-id><pub-id pub-id-type="pmid">6732213</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><name><surname>Taccone</surname><given-names>FS</given-names></name><name><surname>Laterre</surname><given-names>PF</given-names></name><name><surname>Spapen</surname><given-names>H</given-names></name><name><surname>Dugernier</surname><given-names>T</given-names></name><name><surname>Delattre</surname><given-names>I</given-names></name><name><surname>Layeux</surname><given-names>B</given-names></name><name><surname>De Backer</surname><given-names>D</given-names></name><name><surname>Wittebole</surname><given-names>X</given-names></name><name><surname>Wallemacq</surname><given-names>P</given-names></name><name><surname>Vincent</surname><given-names>JL</given-names></name><name><surname>Jacobs</surname><given-names>F</given-names></name><article-title>Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock</article-title><source>Crit Care</source><year>2010</year><volume>14</volume><fpage>R53</fpage><pub-id pub-id-type="doi">10.1186/cc8945</pub-id><pub-id pub-id-type="pmid">20370907</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><name><surname>van Zanten</surname><given-names>AR</given-names></name><name><surname>Polderman</surname><given-names>KH</given-names></name><name><surname>van Geijlswijk</surname><given-names>IM</given-names></name><name><surname>van der Meer</surname><given-names>GY</given-names></name><name><surname>Schouten</surname><given-names>MA</given-names></name><name><surname>Girbes</surname><given-names>AR</given-names></name><article-title>Ciprofloxacin pharmacokinetics in critically ill patients: a prospective cohort study</article-title><source>J Crit Care</source><year>2008</year><volume>23</volume><fpage>422</fpage><lpage>430</lpage><pub-id pub-id-type="doi">10.1016/j.jcrc.2007.11.011</pub-id><pub-id pub-id-type="pmid">18725050</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><name><surname>Taccone</surname><given-names>FS</given-names></name><name><surname>Laterre</surname><given-names>PF</given-names></name><name><surname>Dugernier</surname><given-names>T</given-names></name><name><surname>Spapen</surname><given-names>H</given-names></name><name><surname>Delattre</surname><given-names>I</given-names></name><name><surname>Wittebole</surname><given-names>X</given-names></name><name><surname>De Backer</surname><given-names>D</given-names></name><name><surname>Layeux</surname><given-names>B</given-names></name><name><surname>Wallemacq</surname><given-names>P</given-names></name><name><surname>Vincent</surname><given-names>JL</given-names></name><name><surname>Jacobs</surname><given-names>F</given-names></name><article-title>Insufficient beta-lactam concentrations in the early phase of severe sepsis and septic shock</article-title><source>Crit Care</source><year>2010</year><volume>14</volume><fpage>R126</fpage><pub-id pub-id-type="doi">10.1186/cc9091</pub-id><pub-id pub-id-type="pmid">20594297</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><name><surname>Roberts</surname><given-names>JA</given-names></name><name><surname>Lipman</surname><given-names>J</given-names></name><name><surname>Blot</surname><given-names>S</given-names></name><name><surname>Rello</surname><given-names>J</given-names></name><article-title>Better outcomes through continuous infusion of time-dependent antibiotics to critically ill patients?</article-title><source>Curr Opin Crit Care</source><year>2008</year><volume>14</volume><fpage>390</fpage><lpage>396</lpage><pub-id pub-id-type="doi">10.1097/MCC.0b013e3283021b3a</pub-id><pub-id pub-id-type="pmid">18614901</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><name><surname>Blot</surname><given-names>S</given-names></name><article-title>MRSA pneumonia: better outcome through continuous infusion of vancomycin?</article-title><source>Crit Care Med</source><year>2005</year><volume>33</volume><fpage>2127</fpage><lpage>2128</lpage><pub-id pub-id-type="doi">10.1097/01.CCM.0000178288.70057.47</pub-id><pub-id pub-id-type="pmid">16148496</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><name><surname>Wysocki</surname><given-names>M</given-names></name><name><surname>Delatour</surname><given-names>F</given-names></name><name><surname>Faurisson</surname><given-names>F</given-names></name><name><surname>Rauss</surname><given-names>A</given-names></name><name><surname>Pean</surname><given-names>Y</given-names></name><name><surname>Misset</surname><given-names>B</given-names></name><name><surname>Thomas</surname><given-names>F</given-names></name><name><surname>Timsit</surname><given-names>JF</given-names></name><name><surname>Similowski</surname><given-names>T</given-names></name><name><surname>Mentec</surname><given-names>H</given-names></name><name><surname>Mier</surname><given-names>L</given-names></name><name><surname>Dreyfuss</surname><given-names>D</given-names></name><article-title>Continuous <italic>versus</italic> intermittent infusion of vancomycin in severe Staphylococcal infections: prospective multicenter randomized study</article-title><source>Antimicrob Agents Chemother</source><year>2001</year><volume>45</volume><fpage>2460</fpage><lpage>2467</lpage><pub-id pub-id-type="doi">10.1128/AAC.45.9.2460-2467.2001</pub-id><pub-id pub-id-type="pmid">11502515</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><name><surname>Akers</surname><given-names>KS</given-names></name><name><surname>Cota</surname><given-names>JM</given-names></name><name><surname>Chung</surname><given-names>KK</given-names></name><name><surname>Renz</surname><given-names>EM</given-names></name><name><surname>Mende</surname><given-names>K</given-names></name><name><surname>Murray</surname><given-names>CK</given-names></name><article-title>Serum vancomycin levels resulting from continuous or intermittent infusion in critically ill burn patients with or without continuous renal replacement therapy</article-title><source>J Burn Care Res</source><year>2012</year><volume>33</volume><fpage>e254</fpage><lpage>e262</lpage><pub-id pub-id-type="doi">10.1097/BCR.0b013e31825042fa</pub-id><pub-id pub-id-type="pmid">22878490</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><name><surname>Vuagnat</surname><given-names>A</given-names></name><name><surname>Stern</surname><given-names>R</given-names></name><name><surname>Lotthe</surname><given-names>A</given-names></name><name><surname>Schuhmacher</surname><given-names>H</given-names></name><name><surname>Duong</surname><given-names>M</given-names></name><name><surname>Hoffmeyer</surname><given-names>P</given-names></name><name><surname>Bernard</surname><given-names>L</given-names></name><article-title>High dose vancomycin for osteomyelitis: continuous <italic>vs.</italic> intermittent infusion</article-title><source>J Clin Pharm Ther</source><year>2004</year><volume>29</volume><fpage>351</fpage><lpage>357</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2710.2004.00572.x</pub-id><pub-id pub-id-type="pmid">15271102</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><name><surname>Rello</surname><given-names>J</given-names></name><name><surname>Sole-Violan</surname><given-names>J</given-names></name><name><surname>Sa-Borges</surname><given-names>M</given-names></name><name><surname>Garnacho-Montero</surname><given-names>J</given-names></name><name><surname>Munoz</surname><given-names>E</given-names></name><name><surname>Sirgo</surname><given-names>G</given-names></name><name><surname>Olona</surname><given-names>M</given-names></name><name><surname>Diaz</surname><given-names>E</given-names></name><article-title>Pneumonia caused by oxacillin-resistant Staphylococcus aureus treated with glycopeptides</article-title><source>Crit Care Med</source><year>2005</year><volume>33</volume><fpage>1983</fpage><lpage>1987</lpage><pub-id pub-id-type="doi">10.1097/01.CCM.0000178180.61305.1D</pub-id><pub-id pub-id-type="pmid">16148469</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><name><surname>De Waele</surname><given-names>JJ</given-names></name><name><surname>Danneels</surname><given-names>I</given-names></name><name><surname>Depuydt</surname><given-names>P</given-names></name><name><surname>Decruyenaere</surname><given-names>J</given-names></name><name><surname>Bourgeois</surname><given-names>M</given-names></name><name><surname>Hoste</surname><given-names>E</given-names></name><article-title>Factors associated with inadequate early vancomycin levels in critically ill patients treated with continuous infusion</article-title><source>Int J Antimicrob Agents</source><year>2013</year><volume>41</volume><fpage>434</fpage><lpage>438</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2012.12.015</pub-id><pub-id pub-id-type="pmid">23410793</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><name><surname>Golenia</surname><given-names>BS</given-names></name><name><surname>Levine</surname><given-names>AR</given-names></name><name><surname>Moawad</surname><given-names>IM</given-names></name><name><surname>Yeh</surname><given-names>DD</given-names></name><name><surname>Arpino</surname><given-names>PA</given-names></name><article-title>Evaluation of a vancomycin dosing nomogram based on the modification of diet in renal disease equation in intensive care unit patients</article-title><source>J Crit Care</source><year>2013</year><volume>28</volume><fpage>710</fpage><lpage>716</lpage><pub-id pub-id-type="doi">10.1016/j.jcrc.2013.01.004</pub-id><pub-id pub-id-type="pmid">23499418</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="other"><collab>European Committee on Antimicrobial Susceptibility Testing</collab><article-title>Data from the EUCAST MIC distribution website</article-title><source>European Committee on Antimicrobial Susceptibility Testing. Data from the EUCAST MIC distribution website, last accessed 09 May 2013</source></mixed-citation></ref></ref-list></back></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001637 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 001637 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé= PMC:4075416
|texte= Does contemporary vancomycin dosing achieve therapeutic targets in a heterogeneous clinical cohort of critically ill patients? Data from the multinational DALI study
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/RBID.i -Sk "pubmed:24887569" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |